<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1519" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1519/" /><meta name="ncbi_pagename" content="Alpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Alpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Alpha-1 Antitrypsin Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/01/19" /><meta name="citation_author" content="James K Stoller" /><meta name="citation_author" content="Felicitas L Lacbawan" /><meta name="citation_author" content="Loutfi S Aboussouan" /><meta name="citation_pmid" content="20301692" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1519/" /><meta name="citation_keywords" content="AAT Deficiency" /><meta name="citation_keywords" content="A1AT Deficiency" /><meta name="citation_keywords" content="AATD" /><meta name="citation_keywords" content="A1AT Deficiency" /><meta name="citation_keywords" content="AATD" /><meta name="citation_keywords" content="AAT Deficiency" /><meta name="citation_keywords" content="Alpha-1-antitrypsin" /><meta name="citation_keywords" content="SERPINA1" /><meta name="citation_keywords" content="Alpha-1 Antitrypsin Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Alpha-1 Antitrypsin Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="James K Stoller" /><meta name="DC.Contributor" content="Felicitas L Lacbawan" /><meta name="DC.Contributor" content="Loutfi S Aboussouan" /><meta name="DC.Date" content="2017/01/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1519/" /><meta name="description" content="Alpha-1 antitrypsin deficiency (AATD) is characterized by an increased risk for: chronic obstructive pulmonary disease (i.e., emphysema, persistent airflow obstruction, and/or chronic bronchitis) in adults; liver disease in children and adults; panniculitis; and c-ANCA positive vasculitis. Emphysema, sometimes with associated bronchiectasis, is the most common manifestation of AATD. Smoking is the major factor influencing the course of chronic obstructive pulmonary disease (COPD). The onset of respiratory disease in smokers with AATD is characteristically between ages 40 and 50 years; in non-smokers, the onset can be delayed to the sixth decade, and some non-smokers never develop COPD. Non-smokers may have a normal life span. Although reported, emphysema in children with AATD is extremely rare. AATD-associated liver disease, which is present in only a small portion of affected children, manifests as obstructive jaundice and increased serum aminotransferase levels in the early days and months of life. The incidence of liver disease increases with age. Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease. The risk for hepatocellular carcinoma (HCC) is increased in individuals with AATD." /><meta name="og:title" content="Alpha-1 Antitrypsin Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Alpha-1 antitrypsin deficiency (AATD) is characterized by an increased risk for: chronic obstructive pulmonary disease (i.e., emphysema, persistent airflow obstruction, and/or chronic bronchitis) in adults; liver disease in children and adults; panniculitis; and c-ANCA positive vasculitis. Emphysema, sometimes with associated bronchiectasis, is the most common manifestation of AATD. Smoking is the major factor influencing the course of chronic obstructive pulmonary disease (COPD). The onset of respiratory disease in smokers with AATD is characteristically between ages 40 and 50 years; in non-smokers, the onset can be delayed to the sixth decade, and some non-smokers never develop COPD. Non-smokers may have a normal life span. Although reported, emphysema in children with AATD is extremely rare. AATD-associated liver disease, which is present in only a small portion of affected children, manifests as obstructive jaundice and increased serum aminotransferase levels in the early days and months of life. The incidence of liver disease increases with age. Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease. The risk for hepatocellular carcinoma (HCC) is increased in individuals with AATD." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1519/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/alpha1-a/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1519/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88B3EBE04077C100000000061C0244.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1519_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1519_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/alkap/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/a-mannosidosis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1519_"><span class="title" itemprop="name">Alpha-1 Antitrypsin Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: AAT Deficiency, A1AT Deficiency, AATD</div><p class="contrib-group"><span itemprop="author">James K Stoller</span>, MD, MS, <span itemprop="author">Felicitas L Lacbawan</span>, MD, and <span itemprop="author">Loutfi S Aboussouan</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1519_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1519_ai__"><div class="contrib half_rhythm"><span itemprop="author">James K Stoller</span>, MD, MS<div class="affiliation small">Respiratory and Education Institutes<br />Cleveland Clinic<br />Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.fcc@jellots" class="oemail">gro.fcc@jellots</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Felicitas L Lacbawan</span>, MD<div class="affiliation small">Molecular Pathology<br />Pathology and Laboratory Medicine Institute<br />Cleveland Clinic<br />Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.fcc@fwabcal" class="oemail">gro.fcc@fwabcal</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Loutfi S Aboussouan</span>, MD<div class="affiliation small">Respiratory Institute<br />Cleveland Clinic<br />Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.fcc@lssuoba" class="oemail">gro.fcc@lssuoba</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 27, 2006</span>; Last Revision: <span itemprop="dateModified">January 19, 2017</span>.</p><p><em>Estimated reading time: 35 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="alpha1-a.Summary" itemprop="description"><h2 id="_alpha1-a_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Alpha-1 antitrypsin deficiency (AATD) is characterized by an increased risk for: chronic obstructive pulmonary disease (i.e., emphysema, persistent airflow obstruction, and/or chronic bronchitis) in adults; liver disease in children and adults; panniculitis; and c-ANCA positive vasculitis. Emphysema, sometimes with associated bronchiectasis, is the most common manifestation of AATD. Smoking is the major factor influencing the course of chronic obstructive pulmonary disease (COPD). The onset of respiratory disease in smokers with AATD is characteristically between ages 40 and 50 years; in non-smokers, the onset can be delayed to the sixth decade, and some non-smokers never develop COPD. Non-smokers may have a normal life span. Although reported, emphysema in children with AATD is extremely rare. AATD-associated liver disease, which is present in only a small portion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, manifests as obstructive jaundice and increased serum aminotransferase levels in the early days and months of life. The incidence of liver disease increases with age. Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease. The risk for hepatocellular carcinoma (HCC) is increased in individuals with AATD.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of AATD relies on demonstration of low serum concentration of alpha-1 antitrypsin (AAT) and either detection of a functionally deficient AAT protein variant by protease inhibitor (PI) typing or detection of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SERPINA1</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding alpha-1 antitrypsin. Note: The unconventional nomenclature of <i>SERPINA1</i> alleles is based on electrophoretic protein variants that were identified long before the gene (<i>SERPINA1)</i> was known. Alleles were named with the prefix PI* (protease inhibitor*) serving as an alias for the gene. Using this nomenclature, the most common (normal) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is PI*M and the most common pathogenic allele is PI*Z.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> COPD is treated with standard therapy. Intravenous augmentation therapy (regular infusion of purified human AAT to elevate deficient serum AAT concentrations) has been recommended for individuals with established fixed airflow obstruction (especially when FEV<sub>1</sub> is 35%-60% of predicted). Lung transplantation may be an appropriate option for individuals with end-stage lung disease. Liver transplantation is the definitive treatment for advanced liver disease. The often painful nodular lesions of panniculitis may resolve spontaneously or after dapsone or doxycycline therapy. When refractory to conventional treatment, panniculitis has responded to intravenous AAT augmentation therapy in higher than conventional doses.</p><p><i>Prevention of secondary complications:</i> To lessen the progression of lung disease, yearly vaccination against influenza and pneumococcus; to lessen the risk of liver disease, vaccination against hepatitis A and B.</p><p><i>Surveillance:</i></p><ul><li class="half_rhythm"><div>All individuals with severe AATD: Pulmonary function tests, including spirometry with bronchodilators and diffusing capacity measurements, every six to 12 months.</div></li><li class="half_rhythm"><div>All individuals with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>: Periodic evaluation of liver function in order to detect liver disease.</div></li><li class="half_rhythm"><div>All persons with established liver disease: Periodic (i.e., every 6-12 months) ultrasound examination of the liver to monitor for fibrotic changes and HCC.</div></li></ul><p><i>Agents/circumstances to avoid:</i> Smoking (both active and passive), occupations with exposure to environmental pollutants used in agriculture, mineral dust, gas, and fumes.</p><p><i>Evaluation of relatives at risk:</i> Evaluation of parents, older and younger sibs, and offspring of an individual with severe AATD in order to identify as early as possible those relatives who would benefit from institution of treatment and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>AATD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. When both parents are heterozygotes (e.g., PI*MZ), each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected (PI*ZZ), a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (PI*MZ), and a 25% chance of being unaffected and not a carrier (PI*MM). In the uncommon instance in which one parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> (PI*ZZ) and one parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (PI*MZ), the risk to each sib of being homozygous (PI*ZZ) is 50%. Unless an individual with AATD has children with a reproductive partner who is affected or a carrier, his/her offspring will be obligate heterozygotes (carriers) for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible once the pathogenic <i>SERPINA1</i> variants have been identified in the family.</p></div></div><div id="alpha1-a.Diagnosis"><h2 id="_alpha1-a_Diagnosis_">Diagnosis</h2><div id="alpha1-a.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Alpha-1 antitrypsin deficiency (AATD) should be suspected in individuals with evidence of:</p><ul><li class="half_rhythm"><div>Chronic obstructive pulmonary disease (i.e., emphysema, persistent airflow obstruction, and/or chronic bronchitis); AND/OR</div></li><li class="half_rhythm"><div>Any of the following:</div><ul><li class="half_rhythm"><div>Liver disease at any age, including obstructive jaundice in infancy</div></li><li class="half_rhythm"><div>C-ANCA positive vasculitis (i.e., granulomatosis with polyangiitis)</div></li><li class="half_rhythm"><div>Necrotizing panniculitis</div></li></ul></li></ul></div><div id="alpha1-a.Confirming_the_Diagnosis"><h3>Confirming the Diagnosis</h3><p>The diagnosis of AATD relies on <b>A</b> and <b>either B or C</b>:</p><p><b>A. Demonstration of low serum concentration of the protein alpha-1 antitrypsin (AAT).</b> A variety of techniques have been used to measure serum AAT concentration; currently the most commonly used technique is nephelometry.</p><ul><li class="half_rhythm"><div>Normal serum levels are 20-53 &#x000b5;mol/L or approximately 100-220 mg/dL by nephelometry.</div></li><li class="half_rhythm"><div>Serum levels observed in AATD with lung disease are usually &#x0003c;57 mg/dL.</div></li></ul><p>Note:</p><p>(1) Serum levels of AAT may be increased in the following circumstances:</p><ul><li class="half_rhythm"><div>Up to a fourfold rise as an acute phase reactant during episodes of acute inflammation, cancer, and liver disease in individuals without AATD</div></li><li class="half_rhythm"><div>As an acute phase reactant during episodes of acute inflammation in heterozygotes for one <i>SERPINA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and those with mild AATD</div></li><li class="half_rhythm"><div>In pregnancy and in women on estrogen therapy</div></li><li class="half_rhythm"><div>In persons receiving blood transfusions or intravenous augmentation therapy (i.e., purified pooled human plasma AAT)</div></li></ul><p>(2) Despite the increase in serum levels of AAT observed in these circumstances, the normally decreased serum levels of AAT in individuals with severe AATD (resulting from homozygosity for the PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) are unlikely to rise high enough to be considered in the normal range.</p><p><b>B. Detection of a functionally deficient AAT protein variant by protease inhibitor (PI) typing.</b> PI typing is performed by polyacrylamide gel <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> (IEF) electrophoresis of serum in a gradient between pH 4 and 5.</p><ul><li class="half_rhythm"><div>Electrophoretic AAT protein variants (<a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>) are designated by letters based on their migration pattern. For example, the normal AAT protein (designated M) migrates in the middle of the isoelectric field. The abnormal AAT deficiency protein (designated Z) migrates most slowly. Other variants have been given additional alphabetic designations; some rare variants have been named by place of origin of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. See <a href="/books/NBK1519/bin/alpha1-a-Table5.pdf">Table 5</a> (pdf).</div></li><li class="half_rhythm"><div>Because a range of AAT protein variants from normal to deficient can be observed in an IEF assay, a reference of 13 common and five rare AAT protein variants is used to identify the specific AAT protein [<a class="bk_pop" href="#alpha1-a.REF.greene.2013.184">Greene et al 2013</a>].</div></li><li class="half_rhythm"><div>The limitations of IEF include inability to interpret an atypical electrophoretic pattern resulting from rare AAT protein variants and absence of AAT protein resulting from a <i>SERPINA1</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>IEF, the biochemical gold standard test for establishing the diagnosis of AATD, may be less costly than <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li></ul><p><b>C. Detection of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SERPINA1</i> pathogenic variants,</b> which confirms a diagnosis of AATD when serum AAT levels are not measured, PI typing is not performed, or results from serum AAT levels or PI typing are discordant:</p><ul><li class="half_rhythm"><div class="half_rhythm">Molecular genetic testing may begin by a targeted approach for the most frequent <i>SERPINA1</i> pathogenic variants, followed by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> (<a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.summary_of_molecular_genetic/?report=objectonly" target="object" rid-figpopup="figalpha1aTsummaryofmoleculargenetic" rid-ob="figobalpha1aTsummaryofmoleculargenetic">Table 1</a>).</div><div class="half_rhythm">Note: The nomenclature of <i>SERPINA1</i> alleles is unconventional because it is based on electrophoretic protein variants that were identified long before the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>SERPINA1</i>) was identified [<a class="bk_pop" href="#alpha1-a.REF.cox.1980.429">Cox et al 1980</a>]. Because this older nomenclature is well-established in the literature, it is used in this <i>GeneReview</i>.</div></li><li class="half_rhythm"><div class="half_rhythm"><i>SERPINA1</i> alleles encoding the variant AAT proteins were named with the prefix PI* (protease inhibitor*) serving as an alias for <i>SERPINA1</i> (which had yet to be identified). The four <i>SERPINA1</i> alleles discussed here are the following (see <a href="#alpha1-a.Molecular_Genetics">Molecular Genetics</a> for more details and information on other alleles):</div><ul><li class="half_rhythm"><div><b>PI*M.</b> The most common <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in all populations described to date. Some benign variants of the PI*M allele are designated M1, M2, M3, etc.</div></li><li class="half_rhythm"><div><b>PI*Z.</b> The most common pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> resulting in functionally deficient AAT protein. Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for PI*Z (i.e., PI*ZZ) have severe alpha-1 antitrypsin deficiency (AATD).</div></li><li class="half_rhythm"><div><b>PI*S.</b> A pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> resulting in functionally deficient AAT. It is usually of clinical consequence only in the <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state with another pathogenic allele (e.g., PI*SZ) and when the serum AAT level is &#x0003c;57 mg/dL.</div></li><li class="half_rhythm"><div><b>Null alleles (sometimes designated PI*QO).</b> Pathogenic alleles that result in either no <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> product or no protein production</div></li></ul></li></ul><div id="alpha1-a.T.summary_of_molecular_genetic" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Summary of Molecular Genetic Testing Used in Alpha-1 Antitrypsin Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1519/table/alpha1-a.T.summary_of_molecular_genetic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpha1-a.T.summary_of_molecular_genetic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SERPINA1</i></td><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>2</sup></td><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_alpha1-a.T.summary_of_molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown, rare&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alpha1-a.TF.1.1"><p class="no_margin">See <a href="/books/NBK1519/#alpha1-a.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#alpha1-a.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="alpha1-a.TF.1.2"><p class="no_margin">Targeted analysis for pathogenic variants is typically specific for detecting the pathogenic alleles PI*Z and PI*S. See <a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.relationship_of_aat_protein_v/?report=objectonly" target="object" rid-figpopup="figalpha1aTrelationshipofaatproteinv" rid-ob="figobalpha1aTrelationshipofaatproteinv">Table 3</a></p></div></dd><dt>3. </dt><dd><div id="alpha1-a.TF.1.3"><p class="no_margin">95% of AATD results from the pathogenic alleles PI*Z and PI*S.</p></div></dd><dt>4. </dt><dd><div id="alpha1-a.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="alpha1-a.TF.1.5"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Included in the variety of methods that may be used are: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>6. </dt><dd><div id="alpha1-a.TF.1.6"><p class="no_margin">Rare <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> and whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions have been reported; see HGMD in <a href="/books/NBK1519/#alpha1-a.molgen.TA">Table A</a>, <b>HGMD</b>.</p></div></dd></dl></div></div></div></div><div id="alpha1-a.Testing_Strategy"><h3>Testing Strategy</h3><p>Though the optimal algorithm for laboratory testing is not well defined, guidelines for the diagnosis and management of AATD by the American Thoracic Society/European Respiratory Society include recommended indications for genetic testing for AATD [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>].</p><div id="alpha1-a.T.clinical_indications_for_gene" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical Indications for Genetic Testing</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1519/table/alpha1-a.T.clinical_indications_for_gene/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpha1-a.T.clinical_indications_for_gene_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" style="text-align:left;vertical-align:middle;">Clinical Indication</th><th id="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2" colspan="4" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Genetic Testing</th></tr><tr><th headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2" id="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Recommended</th><th headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2" id="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To be Decided in Discussion w/Patient</th><th headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2" id="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not Recommended</th><th headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2" id="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Discouraged</th></tr></thead><tbody><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Pulmonary</b></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Symptomatic adult w/emphysema, COPD, asthma w/incompletely reversible airflow obstruction</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymptomatic w/persistent obstruction &#x00026; risk factors</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Symptomatic adult w/emphysema, COPD, asthma w/incompletely reversible airflow obstruction (in countries with prevalence &#x0003c; N America or Europe)</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adults with bronchiectasis w/out evident etiology</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adolescents w/persistent airflow obstruction</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymptomatic w/persistent airflow obstruction &#x00026; no risk factors</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adults w/asthma &#x00026; completely reversible airflow obstruction</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Extra-pulmonary</b></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unexplained liver disease</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adult w/necrotizing panniculitis</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adult w/c-ANCA positive vasculitis</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sib of adult w/AATD</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Family history of COPD or liver disease not known to be caused by AATD</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distant relative of an individual w/the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Offspring/parent of an individual w/the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sib, offspring, parent, or distant relative of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> individual (e.g., w/the PI*MZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>)</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Carrier status assessment for reproduction planning</b></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individual at high risk for AAT deficiency-related disease</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Partner of individual w/the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> or the PI*MZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Population screening</b></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In countries w/AATD prevalence &#x0003e;1:1500, prevalent smoking, &#x00026; adequate counseling services</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In smokers with normal spirometry</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In countries w/low AATD prevalence, low prevalence of smoking, or inadequate counseling services</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predispositional testing</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predispositional fetal testing</td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_1_2 hd_h_alpha1-a.T.clinical_indications_for_gene_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">x</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from the ATS/ERS Statement [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>]</p></div></dd></dl></div></div></div></div></div><div id="alpha1-a.Clinical_Characteristics"><h2 id="_alpha1-a_Clinical_Characteristics_">Clinical Characteristics</h2><div id="alpha1-a.Clinical_Description"><h3>Clinical Description</h3><p>Alpha-1 antitrypsin deficiency (AATD) can present with hepatic dysfunction in individuals from infancy to adulthood and with obstructive lung disease and/or bronchiectasis, characteristically in individuals older than age 30 years. Phenotypic expression varies within and between families.</p><p>The severity of AATD depends on the <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and resultant serum AAT level. Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for severe deficiency alleles (i.e., PI*ZZ) have low serum AAT levels, placing them at increased risk for chronic obstructive pulmonary disease (COPD) (see <a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.relationship_of_aat_protein_v/?report=objectonly" target="object" rid-figpopup="figalpha1aTrelationshipofaatproteinv" rid-ob="figobalpha1aTrelationshipofaatproteinv">Table 3</a>). Individuals with alleles associated with intra-hepatic inclusions (e.g., Z, M<sub>malton</sub>) are also at increased risk of developing liver disease.</p><div id="alpha1-a.Lung_Disease"><h4>Lung Disease</h4><p><b>Adult-onset lung disease.</b> Chronic obstructive pulmonary disease (COPD), specifically emphysema and/or chronic bronchitis, is the most common clinical manifestation of AATD.</p><p>In adults, smoking is the major factor that can accelerate the development of COPD. Although the natural history of AATD varies, depending in part on what has brought the patient to medical attention (e.g., lung symptoms, liver symptoms, asymptomatic relative of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual), the onset of respiratory disease in smokers with AATD is characteristically between ages 40 and 50 years [<a class="bk_pop" href="#alpha1-a.REF.tanash.2008.1091">Tanash et al 2008</a>]. Non-smokers may have a normal life span, but can also develop lung and/or liver disease.</p><p>Patients with severe AATD may manifest the usual signs and symptoms of obstructive lung disease, asthma, and chronic bronchitis (e.g., dyspnea, cough, wheezing, and sputum production) [<a class="bk_pop" href="#alpha1-a.REF.mcelvaney.1997.394">McElvaney et al 1997</a>]. For example, in the National Heart, Lung, and Blood Institute (NHLBI) Registry, with 1129 participants with severe deficiency of AAT, 84% described dyspnea, 76% wheezed with an upper respiratory tract infection, and 50% reported cough and phlegm [<a class="bk_pop" href="#alpha1-a.REF.mcelvaney.1997.394">McElvaney et al 1997</a>, <a class="bk_pop" href="#alpha1-a.REF.eden.2003.765">Eden et al 2003</a>]. Of note, the prevalence of AATD in persons with asthma does not differ from that found in the general population [<a class="bk_pop" href="#alpha1-a.REF.wencker.2002.319">Wencker et al 2002</a>, <a class="bk_pop" href="#alpha1-a.REF.miravitlles.2003.404">Miravitlles et al 2003</a>].</p><p>Most (~95%) of individuals with severe AATD have evidence of bronchiectasis on chest CT, with 27% demonstrating clinical symptoms of bronchiectasis [<a class="bk_pop" href="#alpha1-a.REF.parr.2007.1215">Parr et al 2007</a>].</p><p>In individuals with AATD:</p><ul><li class="half_rhythm"><div>Chest CT shows loss of lung parenchyma and hyperlucency. In contrast to the usual pattern observed in centriacinar emphysema (emphysematous changes more pronounced in the lung apices than bases), the pattern observed in two thirds of individuals with AATD is that of more pronounced emphysematous changes in the bases than apices [<a class="bk_pop" href="#alpha1-a.REF.parr.2004.1172">Parr et al 2004</a>].</div></li><li class="half_rhythm"><div>Lung function tests show decreased expiratory airflow, increased lung volumes, and decreased diffusing capacity. Approximately 60% of patients with AATD-associated emphysema demonstrate a component of reversible airflow obstruction, defined as a 200 mL and 12% increase in the post-bronchodilator FEV<sub>1</sub> and/or FVC.</div></li></ul><p>Under-recognition of AATD often causes a long delay between first symptoms and initial diagnosis of AATD (i.e., 5-7 years) and many patients report seeing multiple physicians before the diagnosis is first established.</p><p><b>Childhood-onset lung disease.</b> Although reported, emphysema in children with AATD is extremely rare and may result from the coexistence of other unidentified genetic factors affecting the lung [<a class="bk_pop" href="#alpha1-a.REF.cox.1979.467">Cox &#x00026; Talamo 1979</a>].</p><p>Studies that followed newborns with severe AAT deficiency through age 32 years showed that most adults did not smoke and lacked physiologic and CT evidence of emphysema [<a class="bk_pop" href="#alpha1-a.REF.bernsp_ng.2009.861">Bernsp&#x000e5;ng et al 2009</a>]. Longer term follow-up studies are not currently available. In most observational studies, the mean age of individuals with lung disease is in the fifth decade [<a class="bk_pop" href="#alpha1-a.REF.seersholm.1997.2260">Seersholm et al 1997</a>, <a class="bk_pop" href="#alpha1-a.REF.aadrsg.1998.49">AADRSG 1998</a>].</p><p><b>Risk for lung disease in PI*MZ heterozygotes.</b> Approximately 3% of North Americans are PI*MZ heterozygotes. PI*MZ heterozygotes are generally not considered to be at significantly increased risk for clinical emphysema; however, meta-analyses suggest the possibility of a subpopulation of PI*MZ heterozygotes at risk for accelerated lung disease [<a class="bk_pop" href="#alpha1-a.REF.hersh.2004.843">Hersh et al 2004</a>, <a class="bk_pop" href="#alpha1-a.REF.s_rheim.2010.1125">S&#x000f8;rheim et al 2010</a>]. Of note, slight abnormalities of lung function can be present without clinical symptoms. Emerging information also suggests that emphysema may be present on chest CT without evidence of impaired lung function on pulmonary function tests [<a class="bk_pop" href="#alpha1-a.REF.smith.2014.94.e7">Smith et al 2014</a>].</p><p><b>Risk for lung disease in persons with the PI*SZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>.</b> Individuals who smoke and have the PI*SZ genotype with serum AAT levels below the protective threshold value have a slightly increased disease risk, especially if they smoke.</p><div id="alpha1-a.T.relationship_of_aat_protein_v" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Relationship of AAT Protein Variants to Serum AAT Levels and Emphysema Risk in Adults</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1519/table/alpha1-a.T.relationship_of_aat_protein_v/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpha1-a.T.relationship_of_aat_protein_v_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" style="text-align:left;vertical-align:middle;">AAT Protein Variants</th><th id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Prevalence (%)</th><th id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Serum AAT Levels</th><th id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" style="text-align:left;vertical-align:middle;">Emphysema Risk</th></tr><tr><th headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2" id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Worldwide</th><th headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2" id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">North America</th><th headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2" id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Europe</th><th headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3" id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">"True Level"&#x000a0;<sup>1</sup> Mean (5<sup>th</sup> %ile&#x02013;95th %ile)</th><th headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3" id="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Commercial Standard&#x000a0;<sup>2</sup> Median (5<sup>th</sup> %ile&#x02013;95th %ile)</th></tr></thead><tbody><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>MM</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96.3</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">93.0</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">91.1</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33 (20&#x02013;53)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">147 (102&#x02013;254)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Background</td></tr><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>MS</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4.8</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.6</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33 (18&#x02013;52)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">125 (86&#x02013;218)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Background</td></tr><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>MZ</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.8</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.1</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.9</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25.4 (15&#x02013;42)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90 (62&#x02013;151)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Background</td></tr><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SS</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.08</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.1</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.3</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28 (20&#x02013;48)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95 (43&#x02013;154)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Background</td></tr><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SZ</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.02</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.1</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.1</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.5 (10&#x02013;23)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">62 (33&#x02013;108)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-50%</td></tr><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>ZZ</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.003</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.01</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.01</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.3 (3.4&#x02013;7)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;29 (&#x02264;29&#x02013;52)</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-100%</td></tr><tr><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Null-Null</b></td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_2 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_3 hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_alpha1-a.T.relationship_of_aat_protein_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#alpha1-a.REF.brantly.1991.703">Brantly et al [1991]</a>, <a class="bk_pop" href="#alpha1-a.REF.stoller.2005.2225">Stoller &#x00026; Aboussouan [2005]</a>, <a class="bk_pop" href="#alpha1-a.REF.de_serres.2012.277">de Serres &#x00026; Blanco [2012]</a>, <a class="bk_pop" href="#alpha1-a.REF.bornhorst.2013.1000">Bornhorst et al [2013]</a></p></div></dd><dt>1. </dt><dd><div id="alpha1-a.TF.3.1"><p class="no_margin">&#x000b5;mol/L</p></div></dd><dt>2. </dt><dd><div id="alpha1-a.TF.3.2"><p class="no_margin">mg/dL</p></div></dd></dl></div></div></div><p>Note: An attempt to correlate serum AAT levels with protein variants in children showed trends similar to those seen in adults [<a class="bk_pop" href="#alpha1-a.REF.donato.2012.398">Donato et al 2012</a>].</p></div><div id="alpha1-a.Liver_Disease"><h4>Liver Disease</h4><p><b>Childhood-onset liver disease.</b> The most common manifestation of AATD-associated liver disease is jaundice, with hyperbilirubinemia and raised serum aminotransferase levels in the early days and months of life.</p><p>Liver abnormalities develop in only a portion of children with AATD. In a study of 200,000 Swedish children who were followed up after <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for AATD, 18% of those with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> developed clinically recognized liver abnormalities and 2.4% developed liver cirrhosis with death in childhood [<a class="bk_pop" href="#alpha1-a.REF.sveger.1976.1316">Sveger 1976</a>, <a class="bk_pop" href="#alpha1-a.REF.sveger.1988.847">Sveger 1988</a>]. Liver damage may progress slowly [<a class="bk_pop" href="#alpha1-a.REF.volpert.2000.258">Volpert et al 2000</a>].</p><p>In a follow-up study of 44 children with AATD-associated liver disease initially manifesting as cirrhosis or portal hypertension, outcomes ranged from liver transplantation in two, to relatively healthy lives up to 23 years after diagnosis in seven [<a class="bk_pop" href="#alpha1-a.REF.migliazza.2000.5">Migliazza et al 2000</a>].</p><p>It is not known why only a small proportion of children with early hyperbilirubinemia have continued liver destruction leading to cirrhosis. The overall risk that an individual with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> will develop severe liver disease in childhood is generally low (~2%); the risk is higher among sibs of a child with the PI*ZZ genotype and liver disease.</p><ul><li class="half_rhythm"><div>When liver abnormalities in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are mild and resolve, the risk of liver disease in sibs with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is approximately 13%.</div></li><li class="half_rhythm"><div>When liver disease in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is severe, the risk for severe liver disease in sibs with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> may be approximately 40% [<a class="bk_pop" href="#alpha1-a.REF.cox.2004.468">Cox 2004</a>].</div></li></ul><p><b>Adult-onset liver disease.</b> Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease. Liver disease is more common in men than women.</p><p>In an early series of 246 individuals with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>, liver disease was observed in 12%. In other series, between 15% and 19% of individuals over age 50 years with AATD and the PI*ZZ genotype developed cirrhosis. The risk for liver disease at age 20-40 years is approximately 2% and at age 41-50 years approximately 4% [<a class="bk_pop" href="#alpha1-a.REF.cox.1983.221">Cox &#x00026; Smyth 1983</a>].</p><p>Later autopsy studies suggest that the prevalence of liver disease may be as high as 40% in older individuals who have never smoked and do not have COPD [<a class="bk_pop" href="#alpha1-a.REF.eriksson.1987.461">Eriksson 1987</a>].</p><p><b>Hepatocellular carcinoma (HCC).</b> The risk for HCC among individuals with AATD and the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is several times that typically associated with liver cirrhosis. The incidence of hepatocellular carcinoma is estimated at more than 1.5% per year [<a class="bk_pop" href="#alpha1-a.REF.bruix.2005.1208">Bruix et al 2005</a>]. This increased risk has been attributed to failure of apoptosis of injured cells with retained Z protein, which sends a chronic regeneration signal to hepatocytes with a lesser load of retained Z protein [<a class="bk_pop" href="#alpha1-a.REF.perlmutter.2006.233">Perlmutter 2006</a>].</p><p><b>Liver pathology.</b> AATD liver inclusions are visualized as bright pink globules of various sizes, using periodic acid-Schiff (PAS) stain following diastase treatment (PAS-D). The extent of inclusion formation varies considerably; the number and size of liver inclusions increases with age. Inclusions are not observed before age 12 weeks. Note: Liver biopsy, when indicated in the evaluation of patients with liver disease, may show periodic Schiff (PAS) positive diastase-resistant inclusion bodies which are suggestive of but not pathognomonic for AATD.</p><p>In infants with AATD, inclusions may be fine and granular and difficult to identify in percutaneous liver biopsy specimens. They are also observed in bile duct epithelium [<a class="bk_pop" href="#alpha1-a.REF.cutz.1979.1">Cutz &#x00026; Cox 1979</a>].</p><p>Histopathologic features of childhood-onset liver disease include intrahepatic cholestasis, varying degrees of hepatocellular injury, and moderate fibrosis with inflammatory cells in portal areas.</p><p>Because liver inclusions indicate the presence of at least one PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, histologic examination of the liver cannot distinguish between individuals who are PI*MZ heterozygotes and PI*ZZ homozygotes. Furthermore, visualization of inclusions may be variable among PI*MZ heterozygotes.</p><p>The PI*MZ and PI*SZ genotypes are not associated with an increased risk for childhood liver disease; however, on occasion, elevated levels of liver enzymes that resolve have been observed. In a study of 58 <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> children showing signs of liver involvement during the first six months of life, almost all had normal values of liver enzymes at ages 12 months, five years, and ten years [<a class="bk_pop" href="#alpha1-a.REF.pittschieler.2002.239">Pittschieler 2002</a>].</p><p>Among adults presenting with chronic liver failure, a greater number of PI*MZ heterozygotes (8.4%) was observed than were reported in the general population (2%-4%) [<a class="bk_pop" href="#alpha1-a.REF.graziadei.1998.1058">Graziadei et al 1998</a>]. Better characterization of the risk for liver disease among PI*MZ heterozygotes must await longitudinal studies.</p></div><div id="alpha1-a.Other_Disease_Associations"><h4>Other Disease Associations</h4><p>While a variety of other illnesses have been observed in individuals with AATD (e.g., membranoproliferative glomerulonephritis, aneurysms, inflammatory bowel disease), only panniculitis and c-ANCA-positive vasculitis have been systematically associated with AATD.</p><ul><li class="half_rhythm"><div><b>Panniculitis</b> occurs in an estimated one in 1000 individuals with AATD [<a class="bk_pop" href="#alpha1-a.REF.aadrsg.1998.49">AADRSG 1998</a>]. Panniculitis characteristically presents as migratory, inflammatory, tender skin nodules which may ulcerate [<a class="bk_pop" href="#alpha1-a.REF.stoller.2008.113">Stoller &#x00026; Piliang 2008</a>]. Sites of trauma (e.g., legs, lower abdomen) are most commonly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Presumably like emphysema in the lung, panniculitis in the skin is caused by unopposed proteolytic damage produced by the PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div><b>C-ANCA-positive vasculitis</b> (e.g., polyangiitis with granulomatosis; previously called Wegener granulomatosis)<b>.</b> Variant <i>SERPINA1</i> alleles are many-fold more prevalent in individuals with c-ANCA-positive vasculitis than in controls: for persons with polyangiitis with granulomatosis the odds ratio for the PI*MZ or PI*MS genotypes was 1.47 compared to the PI*MM <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>, and the odds ratio for the PI*ZZ, PI*SS, or PI*SZ genotypes was 14.6 compared to the PI*MM genotype.</div></li></ul></div></div><div id="alpha1-a.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The risk for lung disease associated with the following <i>SERPINA1</i> genotypes is summarized in <a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.relationship_of_aat_protein_v/?report=objectonly" target="object" rid-figpopup="figalpha1aTrelationshipofaatproteinv" rid-ob="figobalpha1aTrelationshipofaatproteinv">Table 3</a>.</p><p><b>PI*MM.</b> This <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is associated with a normal serum concentration of AAT and no increased risk of liver or lung disease.</p><p><b>PI*MZ.</b> In general, individuals with this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (especially non-smokers) are not considered to be at increased risk for lung disease. Some emerging data suggest that a subset of individuals with the PI*MZ genotype may experience accelerated lung destruction, especially if they are smokers.</p><p><b>PI*SS.</b> This <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> does not appear to be associated with an increased risk for clinical disease [<a class="bk_pop" href="#alpha1-a.REF.ferrarotti.2012.669">Ferrarotti et al 2012</a>]. The S <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is most common among individuals of Iberian descent.</p><p><b>PI*SZ.</b> This <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is not usually associated with a high risk for liver or lung disease; however, the 20% of individuals with the PI*SZ genotype whose serum AAT levels are below the protective threshold value (57 mg/dL) are at increased risk for lung disease, especially if they are smokers [<a class="bk_pop" href="#alpha1-a.REF.turino.1996.1718">Turino et al 1996</a>].</p><p><b>PI*ZZ.</b> Individuals with this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> have a serum concentration of AAT that is approximately 10%-20% of normal (serum levels of 20-35 mg/dL) and are at high risk for both liver and lung disease. This genotype is present in 95% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with clinical manifestations of AATD. Variable disease expressivity in individuals with the PI*ZZ genotype &#x02013; not accounted for by the presence of known risk factors such as cigarette smoking &#x02013; suggests the existence of other as-yet unidentified genetic disease modifiers.</p><p><b>PI*<a class="def" href="/books/n/gene/glossary/def-item/null/">null</a>-null</b> (sometimes designated PI*QO). Individuals with this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> have no measurable serum AAT secondary to complete lack of synthesis of AAT. Because protein does not accumulate in the liver, these individuals are not at increased risk of developing liver disease; however, they are at high risk of developing lung disease.</p><div id="alpha1-a.Expressivity"><h4>Expressivity</h4><p><i>SERPINA1</i> genotypes (e.g., PI*ZZ) associated with serum AAT levels below the protective threshold value of 57 mg/dL are considered to confer an increased risk of developing lung disease. Although inflammatory insults to the lung such as smoking or occupational exposures can accelerate lung disease, disease expression may still vary. Genetic modifiers that remain poorly understood (e.g., <i>IL10</i> single-nucleotide variants) likely account for some of this variability [<a class="bk_pop" href="#alpha1-a.REF.demeo.2008.114">Demeo et al 2008</a>]. Furthermore, the designation of the "protective threshold" value of 57 mg/dL has been empirically assigned and, though it has provided generally helpful clinical guidance in defining pulmonary risk, may do so imperfectly.</p><p>Individuals with <i>SERPINA1</i> alleles associated with intra-hepatic inclusions (because of abnormal protein folding during translation and resultant intra-hepatocyte polymerization, e.g., Z, M<sub>malton</sub>) are also at risk for developing liver disease.</p></div></div><div id="alpha1-a.Nomenclature"><h3>Nomenclature</h3><p>In some publications, the term alpha-1-protease inhibitor is substituted for alpha-1 antitrypsin (AAT).</p></div><div id="alpha1-a.Prevalence"><h3>Prevalence</h3><p>AATD is one of the most common metabolic disorders in persons of northern European heritage, occurring in approximately one in 5,000-7,000 individuals in North America and one in 1,500-3,000 in Scandinavia. AATD also occurs (in lower frequencies) in all other racial subgroups worldwide [<a class="bk_pop" href="#alpha1-a.REF.campbell.2000">Campbell 2000</a>, <a class="bk_pop" href="#alpha1-a.REF.miravitlles.2000">Miravitlles 2000</a>, <a class="bk_pop" href="#alpha1-a.REF.de_serres.2012.277">de Serres &#x00026; Blanco 2012</a>].</p><p>Within Europe, the highest prevalence of the PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is observed in northern and western countries (mean <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> of 0.0153), gradually decreasing throughout the rest of Europe in a north-to-south gradient, with the lowest prevalence in eastern Europe (0.0092).</p><p>The frequency of the PI*S <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is the highest in southern Europe (0.0564), decreasing in northern Europe (0.0176) [<a class="bk_pop" href="#alpha1-a.REF.luisetti.2004.164">Luisetti &#x00026; Seersholm 2004</a>, <a class="bk_pop" href="#alpha1-a.REF.de_serres.2012.277">de Serres &#x00026; Blanco 2012</a>].</p><p>In an analysis estimating the prevalence of various <i>SERPINA1</i> genotypes in 97 countries (out of 193 countries worldwide), a worldwide total of 181,894 individuals with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> was expected, with nearly 70% of all PI*ZZ genotypes estimated to be in Europe and North/Central America. Northern and central Europe account for 74,000 (41% of the total) and North America for 44,000 (24% of the total). Similarly, 48% of all the PI*SZ genotypes were also estimated to be in northern and central Europe, 20% in North America and Central America, and 16% in South America [<a class="bk_pop" href="#alpha1-a.REF.de_serres.2012.277">de Serres &#x00026; Blanco 2012</a>].</p><p>Despite the clustering of geographic areas with low or high prevalence of the PI*S and PI*Z deficiency alleles, that prevalence is not necessarily shared in immediately adjacent countries [<a class="bk_pop" href="#alpha1-a.REF.de_serres.2012.277">de Serres &#x00026; Blanco 2012</a>]. Populations with intermarriage naturally may reflect <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> frequencies and disease prevalences in the contributing groups. Although deficiency alleles have been described in Asian and African populations (e.g., PI*<sub>Siiyama</sub>), the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is generally rare in these groups [<a class="bk_pop" href="#alpha1-a.REF.de_serres.2012.277">de Serres &#x00026; Blanco 2012</a>].</p></div></div><div id="alpha1-a.Genetically_Related_Allelic_Dis"><h2 id="_alpha1-a_Genetically_Related_Allelic_Dis_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>SERPINA1</i>.</p></div><div id="alpha1-a.Differential_Diagnosis"><h2 id="_alpha1-a_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Lung disease.</b> Alpha-1 antitrypsin deficiency (AATD) appears in the differential diagnosis of chronic obstructive pulmonary disease (COPD), including: emphysema, chronic bronchitis, and bronchiectasis.</p><p><b>Liver disease.</b> AATD appears in the differential diagnosis of chronic hepatitis and cirrhosis. Other diseases to consider include chronic viral hepatitis, hereditary hemochromatosis (see <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-Associated Hereditary Hemochromatosis</a>, <a href="/books/n/gene/jh/">Juvenile Hereditary Hemochromatosis</a>), <a href="/books/n/gene/wilson/">Wilson Disease</a>, non-alcoholic steatohepatitis (NASH), and primary biliary cirrhosis.</p><p>In a study of 85 children with neonatal cholestasis, AATD was among the most common diagnoses (11/85); others were extrahepatic biliary atresia (30/85) and progressive <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> intrahepatic cholestasis (11/85) (see <a href="/books/n/gene/pfic/">ATPB1 Deficiency</a>) [<a class="bk_pop" href="#alpha1-a.REF.fischler.2001a.88">Fischler et al 2001a</a>, <a class="bk_pop" href="#alpha1-a.REF.fischler.2001b.171">Fischler et al 2001b</a>].</p><p>PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> was also high (12%) in a group of 29 individuals with cholestatic jaundice and cirrhosis, when compared with controls (0.5%) [<a class="bk_pop" href="#alpha1-a.REF.lima.2001.287">Lima et al 2001</a>].</p></div><div id="alpha1-a.Management"><h2 id="_alpha1-a_Management_">Management</h2><div id="alpha1-a.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with alpha-1 antitrypsin deficiency (AATD), the following evaluations of lung, liver, skin, and vasculature are recommended:</p><ul><li class="half_rhythm"><div><b>Lungs</b></div><ul><li class="half_rhythm"><div>Pulmonary function tests, including spirometry (with post-bronchodilator testing), lung volumes, diffusing capacity, and measures of oxygenation</div></li><li class="half_rhythm"><div>Chest CT, which is more sensitive for detecting emphysema than pulmonary function tests [<a class="bk_pop" href="#alpha1-a.REF.stolk.2001.648">Stolk et al 2001</a>], as part of the initial evaluation by some clinicians</div></li></ul></li><li class="half_rhythm"><div><b>Liver.</b> Liver biopsy for light microscopy and histochemistry when definition of the precise nature and extent of liver disease is clinically indicated [<a class="bk_pop" href="#alpha1-a.REF.nelson.2012.575">Nelson et al 2012</a>]</div></li><li class="half_rhythm"><div><b>Skin.</b> A detailed history and physical examination to assess for panniculitis</div></li></ul></div><div id="alpha1-a.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="alpha1-a.Lung_Disease_1"><h4>Lung Disease</h4><p>Patients with obstructive lung disease should receive standard therapy for chronic obstructive pulmonary disease (COPD) which may include bronchodilators, inhaled corticosteroids, pulmonary rehabilitation, supplemental oxygen, and vaccinations (e.g., influenza and pneumococcal).</p><p>Specific therapy for AATD-related lung disease, called augmentation therapy, is the periodic intravenous infusion of pooled human serum alpha-1antitrypsin (AAT). Concordant observational studies show that AAT augmentation therapy can slow the rate of FEV<sub>1</sub> decline among individuals with AATD-related emphysema [<a class="bk_pop" href="#alpha1-a.REF.seersholm.1997.2260">Seersholm et al 1997</a>, <a class="bk_pop" href="#alpha1-a.REF.aadrsg.1998.49">AADRSG 1998</a>, <a class="bk_pop" href="#alpha1-a.REF.wencker.1998.428">Wencker et al 1998</a>, <a class="bk_pop" href="#alpha1-a.REF.tonelli.2009.443">Tonelli et al 2009</a>].</p><ul><li class="half_rhythm"><div>Two placebo-controlled randomized controlled trials [<a class="bk_pop" href="#alpha1-a.REF.dirksen.1999.1468">Dirksen et al 1999</a>, <a class="bk_pop" href="#alpha1-a.REF.dirksen.2009.1345">Dirksen et al 2009</a>] have shown trends toward preservation of lung density as determined by chest CT in treated individuals vs. controls.</div></li><li class="half_rhythm"><div>Results from a third placebo-controlled randomized, clinical trial are pending; however, preliminary findings are consistent with slowing of progression of emphysema [<a class="bk_pop" href="#alpha1-a.REF.chapman.2013.a6069">Chapman et al 2013</a>].</div></li></ul><p><a href="#alpha1-a.References">Guidelines</a> available from the <a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society [2003]</a> and from the Canadian Thoracic Society [<a class="bk_pop" href="#alpha1-a.REF.marciniuk.2012">Marciniuk et al 2012</a>]:</p><ul><li class="half_rhythm"><div>Recommend intravenous AAT augmentation therapy for individuals with established emphysema. Of note, the greatest benefit evident is observed in individuals with moderate degrees of airflow obstruction (e.g., FEV<sub>1</sub> 35%-60% predicted).</div></li><li class="half_rhythm"><div>Do not recommend prophylactic treatment with intravenous AAT augmentation therapy for individuals with severe AATD but no demonstrable emphysema.</div></li></ul><p>In addition, the Canadian Thoracic Society guidelines specify that AAT augmentation therapy should be offered to individuals with AATD and evidence of emphysema only when they have stopped smoking and have demonstrated accelerated loss of lung function despite optimal therapy for COPD.</p><p>AATD-related lung disease can be modified in asymptomatic individuals by lifestyle changes, including avoidance of smoking and occupations with exposure to environmental pollutants. It is suspected that regular exercise and good nutrition help maintain lung health.</p><p>Approximately 8% of lung transplants in the US are performed in individuals with COPD related to AATD. Lung transplantation may be an appropriate option for individuals with end-stage lung disease (i.e., FEV<sub>1</sub> &#x0003c;30%) and severe functional impairment despite optimal therapy [<a class="bk_pop" href="#alpha1-a.REF.seersholm.1994.1985">Seersholm et al 1994</a>, <a class="bk_pop" href="#alpha1-a.REF.trulock.1998.269s">Trulock 1998</a>]. Some evidence suggests that among comparably <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with AATD, those who receive a lung transplant survive longer (median survival of 11 years in transplant recipients compared to 5 years in those who do not receive a transplant) [<a class="bk_pop" href="#alpha1-a.REF.tanash.2011.1342">Tanash et al 2011</a>].</p><p>Note: Though effective in specific subsets of patients with AAT-replete COPD [<a class="bk_pop" href="#alpha1-a.REF.fishman.2003.2059">Fishman et al 2003</a>], lung volume reduction surgery confers smaller and shorter-lived improvements in lung function in patients with AATD, and so is not generally recommended [<a class="bk_pop" href="#alpha1-a.REF.stoller.2007.241">Stoller et al 2007</a>].</p></div><div id="alpha1-a.Liver_Disease_1"><h4>Liver Disease</h4><p>Vitamin E therapy improves liver function in infants with the PI*MZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and in children with cholestasis [<a class="bk_pop" href="#alpha1-a.REF.sokol.1986.1263">Sokol et al 1986</a>, <a class="bk_pop" href="#alpha1-a.REF.pittschieler.1991.235">Pittschieler 1991</a>], and could be predicted to help prevent oxidative damage to the lungs. Nonetheless, firm evidence that antioxidant therapy (like Vitamin E) is beneficial in AATD is lacking.</p><p>Liver transplantation, the definitive surgical treatment for advanced liver disease, can restore serum AAT levels to normal because a liver from a donor with a PI*MM <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> produces qualitatively and quantitatively normal AAT [<a class="bk_pop" href="#alpha1-a.REF.francavilla.2000.986">Francavilla et al 2000</a>]. Serial lung function measurements following liver transplantation have been studied in a small number of patients to date (N = 17) with a highly variable course following liver transplant [<a class="bk_pop" href="#alpha1-a.REF.carey.2013.1370">Carey et al 2013</a>]. Overall, 65% of patients experienced a decline in FEV<sub>1</sub> post-liver transplant with the mean decline being modest over an average of 49.2 months post-liver transplant and not achieving statistical significance.</p><p>The risk for childhood-onset liver disease in infants with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> who are breast-fed during the first month of life was reported to be reduced; however, breast-feeding does not confer absolute protection against the development of severe liver disease [<a class="bk_pop" href="#alpha1-a.REF.sveger.1985.3036">Sveger 1985</a>].</p></div><div id="alpha1-a.Other"><h4>Other</h4><p><b>Panniculitis.</b> The often painful nodular lesions of panniculitis may resolve spontaneously or after dapsone or doxycycline therapy [<a class="bk_pop" href="#alpha1-a.REF.yesudian.2004.1222">Yesudian et al 2004</a>]; however, when panniculitis is refractory to conventional treatment, it has been shown (anecdotally) to respond to intravenous AAT augmentation therapy in doses higher than the conventional dose of 60 mg/kg [<a class="bk_pop" href="#alpha1-a.REF.stoller.2008.113">Stoller &#x00026; Piliang 2008</a>]. Of note, it is presumed that the panniculitis improves because AAT augmentation therapy restores the proteolytic screen in the skin, thereby lessening inflammation.</p></div></div><div id="alpha1-a.Prevention_of_Secondary_Complic"><h3>Prevention of Secondary Complications</h3><p>To lessen the progression of lung disease, the following are recommended:</p><ul><li class="half_rhythm"><div>Complete cessation of smoking</div></li><li class="half_rhythm"><div>Avoidance of dusty occupational exposures</div></li><li class="half_rhythm"><div>Yearly vaccination against influenza and pneumococcus</div></li></ul><p>To lessen the risk of liver disease, the following are recommended:</p><ul><li class="half_rhythm"><div>Minimal consumption of alcohol [<a class="bk_pop" href="#alpha1-a.REF.kershaw.2008.66">Kershaw &#x00026; Guidot 2008</a>]</div></li><li class="half_rhythm"><div>Vaccination against hepatitis A and B</div></li></ul></div><div id="alpha1-a.Surveillance"><h3>Surveillance</h3><p><b>Patients with severe AATD</b> should undergo pulmonary function tests (including spirometry with bronchodilators and diffusing capacity measurements) every six to 12 months [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>].</p><p><b>All individuals with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a></b> (including those who did not manifest liver disease in childhood) should undergo periodic evaluation of liver function [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>].</p><p>While current guidelines from the American Thoracic Society recommend regular follow up of liver function tests in adults with AATD [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>], those tests may not reliably detect liver disease in these individuals [<a class="bk_pop" href="#alpha1-a.REF.clark.2012.1278">Clark et al 2012</a>]. For instance, various liver function tests were not significantly different in persons with AATD with or without liver disease, and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the alanine transaminase (ALT) for alpha-1 antitrypsin-associated liver disease was only 12% [<a class="bk_pop" href="#alpha1-a.REF.clark.2012.1278">Clark et al 2012</a>]</p><p>A combination of liver function tests, platelet count, and liver ultrasound examination may be an effective screening method to detect the presence of severe fibrosis or cirrhosis [<a class="bk_pop" href="#alpha1-a.REF.dawwas.2013.502">Dawwas et al 2013</a>].</p><p><b>All patients with established liver disease</b> should have periodic (i.e., every 6-12 months) ultrasound examination of the liver to monitor for fibrotic changes and HCC [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>, <a class="bk_pop" href="#alpha1-a.REF.nelson.2012.575">Nelson et al 2012</a>].</p></div><div id="alpha1-a.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Smoking</b> (both active and passive) is a risk factor for lung disease in individuals with AATD.</p><p><b>Occupational exposure</b> (including exposure to environmental pollutants used in agriculture, mineral dust, gas, and fumes) is an independent risk factor for lung function impairment in individuals with the PI*ZZ <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>.</p></div><div id="alpha1-a.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>The ATS/ERS guidelines recommend evaluation of older and younger sibs of an individual with severe AATD (<a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.clinical_indications_for_gene/?report=objectonly" target="object" rid-figpopup="figalpha1aTclinicalindicationsforgene" rid-ob="figobalpha1aTclinicalindicationsforgene">Table 2</a>) in order to identify as early as possible those who would benefit from institution of treatment and preventive measures.</p><p>The ATS/ERS guidelines also recommend testing for parents and children of individuals with severe AATD.</p><p>Extended <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> analysis beyond first-degree relatives may be indicated in selected instances. For example, the presence of an AATD-associated condition (e.g., COPD, liver disease, panniculitis) in a more distant family member would justify extensive family testing (i.e., of family members beyond parents, sibs, and offspring).</p><p>See <a href="#alpha1-a.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="alpha1-a.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Management of women with AATD during pregnancy should be guided by usual care principles, both for women without clinical disease and for those with liver disease. As noted, emphysema, especially in non-smokers, would not commonly be expected during the usual childbearing age range.</p></div><div id="alpha1-a.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>Inhaled administration of purified AAT</b> can restore AAT levels in the bronchoalveolar fluid. Older studies demonstrated the feasibility of inhaling pooled human plasma-derived AAT &#x02013;currently the subject of ongoing study [<a class="bk_pop" href="#alpha1-a.REF.hubbard.1990.565">Hubbard &#x00026; Crystal 1990</a>, <a class="bk_pop" href="#alpha1-a.REF.sandhaus.2004.904">Sandhaus 2004</a>, <a class="bk_pop" href="#alpha1-a.REF.abusriwil.2006.125">Abusriwil &#x00026; Stockley 2006</a>].</p><p><b>Synthetic inhibitors of human neutrophil elastase</b>, administered intravenously and orally, could theoretically provide protection against proteolytic lung damage. No such drug has yet been approved.</p><p><b>Antioxidant therapy.</b> Vitamins A, C, and E and N-acetylcysteine have been suggested in the treatment of AATD-related emphysema. The efficacy of such treatment has not been evaluated [<a class="bk_pop" href="#alpha1-a.REF.sandhaus.2004.904">Sandhaus 2004</a>].</p><p><b>Synthetic chaperones and polymerization</b> could potentially prevent the intracellular polymerization of AAT implicated in causing intra-hepatocyte inclusions and liver disease. Modest improvement in liver retention and increase in plasma concentrations of AAT was suggested after administration of 4-phenyl-butyric acid (PBA) [<a class="bk_pop" href="#alpha1-a.REF.burrows.2000.1796">Burrows et al 2000</a>]. However, a human randomized trial failed to demonstrate efficacy of 4-PBA [<a class="bk_pop" href="#alpha1-a.REF.teckman.2004.34">Teckman 2004</a>].</p><p>Biochemical data on a peptide that specifically binds to variant AAT encoded by the PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and that inhibits polymerization are promising, but future cellular and animal studies are needed [<a class="bk_pop" href="#alpha1-a.REF.mahadeva.2002.6771">Mahadeva et al 2002</a>, <a class="bk_pop" href="#alpha1-a.REF.parfrey.2004.133">Parfrey et al 2004</a>].</p><p><b>Gene therapy</b> is aimed at introducing a functional copy of <i>SERPINA1</i> into cells to allow production of a normal AAT protein. An alternative approach is to introduce <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) to turn off production of the endogenous abnormal variant protein encoded by the pathogenic <i>SERPINA1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Murine studies transfecting muscle with an adeno-associated virus vector carrying a normal functional human <i>SERPINA1</i> allele have been promising. Human <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> studies are currently under way, with evidence that this approach can sustainably increase serum AAT levels, albeit not yet to therapeutic levels (i.e., exceeding 57 mg/dL, the serum protective threshold value) [<a class="bk_pop" href="#alpha1-a.REF.flotte.2011.1239">Flotte et al 2011</a>].</p><p><b>Drugs to enhance autophagy</b> (e.g., rapamycin and carbamazepine) have shown promise in enhancing serum AAT levels and diminishing liver damage. Human trials are under way; results are pending [<a class="bk_pop" href="#alpha1-a.REF.hidvegi.2010.229">Hidvegi et al 2010</a>, <a class="bk_pop" href="#alpha1-a.REF.kaushal.2010.700">Kaushal et al 2010</a>, <a class="bk_pop" href="#alpha1-a.REF.perlmutter.2011.333">Perlmutter 2011</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="alpha1-a.Other_1"><h3>Other</h3><p><b>Lung volume reduction surgery (LVRS)</b> performed for persons with advanced non-AATD emphysema can (in appropriately selected individuals) improve lung function and enhance survival [<a class="bk_pop" href="#alpha1-a.REF.fishman.2003.2059">Fishman et al 2003</a>]. However, in AATD-associated emphysema, the physiologic improvement following LVRS is more modest and less sustained than in non-AATD COPD [<a class="bk_pop" href="#alpha1-a.REF.gelb.1999.928">Gelb et al 1999</a>, <a class="bk_pop" href="#alpha1-a.REF.stoller.2007.241">Stoller et al 2007</a>]. In a study of 12 individuals with AATD-associated emphysema, postoperative lung function returned to baseline in six to 12 months but showed further deterioration in 24 months [<a class="bk_pop" href="#alpha1-a.REF.cassina.1998.1028">Cassina et al 1998</a>]. Results of the National Emphysema Treatment Trial were similarly unfavorable [<a class="bk_pop" href="#alpha1-a.REF.stoller.2007.241">Stoller et al 2007</a>]; thus, LVRS is generally not recommended for individuals with AATD [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>].</p><p><b>Transgenic/recombinant production of human AAT protein</b> could solve the potential problems of limited supply of AAT purified from human serum and the theoretic transmission of infectious agents. However, past clinical trials of transgenic/recombinant AAT produced in sheep and goats [<a class="bk_pop" href="#alpha1-a.REF.casolaro.1987.2015">Casolaro et al 1987</a>, <a class="bk_pop" href="#alpha1-a.REF.wright.1991.830">Wright et al 1991</a>, <a class="bk_pop" href="#alpha1-a.REF.ziomek.1998.139">Ziomek 1998</a>] were discontinued because of serious immunologic reactions in the lungs of recipients. Results from more recent studies are not currently available.</p></div></div><div id="alpha1-a.Genetic_Counseling"><h2 id="_alpha1-a_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="alpha1-a.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>The disorder alpha-1 antitrypsin deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="alpha1-a.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an individual with ATTD have at least one pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and are usually <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a PI*Z allele (e.g., PI*MZ or PI*SZ); less frequently, a parent may be <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the PI*Z allele (i.e., PI*ZZ).</div></li><li class="half_rhythm"><div>Clinical disease is uncommon in heterozygotes (<a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.relationship_of_aat_protein_v/?report=objectonly" target="object" rid-figpopup="figalpha1aTrelationshipofaatproteinv" rid-ob="figobalpha1aTrelationshipofaatproteinv">Table 3</a>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Risk to sibs depends on the genetic status of the parents.</p><ul><li class="half_rhythm"><div>If both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (e.g., PI*MZ) for a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected (i.e., PI*ZZ), a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (i.e., PI*MZ), and a 25% chance of being unaffected and not a carrier (i.e., PI*MM).</div></li><li class="half_rhythm"><div>If one parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> (i.e., PI*ZZ) for a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and the other parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (e.g., PI*MZ) for a pathogenic allele, each sib has a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (i.e., PI*ZZ) and a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (e.g., PI*MZ).</div></li><li class="half_rhythm"><div>Molecular genetic testing should be offered to all sibs in order to clarify their <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (<a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.clinical_indications_for_gene/?report=objectonly" target="object" rid-figpopup="figalpha1aTclinicalindicationsforgene" rid-ob="figobalpha1aTclinicalindicationsforgene">Table 2</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Unless an individual with AATD has children with a reproductive partner who is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate (unaffected) heterozygotes (carriers) (e.g., PI*MZ).</div></li><li class="half_rhythm"><div>In populations with a high <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency and/or a high rate of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>, the reproductive partner of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may also have one or more <i>SERPINA1</i> pathogenic alleles. Thus, the risk to offspring is most accurately determined after protease inhibitor (PI) typing by <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> of serum or <i>SERPINA1</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the proband's reproductive partner.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (e.g., PI*MZ).</p></div><div id="alpha1-a.Carrier_Detection"><h3>Carrier Detection</h3><p>Carrier testing by protease inhibitor (PI) typing by <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> of serum or <i>SERPINA1</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is possible for sibs and offspring of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Note: Measurement of serum AAT level is not reliable for determining <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status because the range of serum AAT levels among most carriers may overlap the normal serum range [<a class="bk_pop" href="#alpha1-a.REF.bornhorst.2013.1000">Bornhorst et al 2013</a>].</p></div><div id="alpha1-a.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#alpha1-a.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Risk to sibs of developing severe liver disease in infancy</b>. Although the age of onset, severity, type of symptoms, and rate of progression of AATD cannot be predicted in sibs based on <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> some estimates are available on the risk to sibs of developing severe liver disease in infancy [<a class="bk_pop" href="#alpha1-a.REF.cox.2004.468">Cox 2004</a>].</p><ul><li class="half_rhythm"><div>If the parents are carriers (e.g., PI*MZ) but have not had a child with severe liver disease, the risk to offspring of having AATD (25%) AND severe liver disease in childhood (13.6%) is less than 1% (0.64%).</div></li><li class="half_rhythm"><div>If an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual died from severe liver disease in childhood, the risk to sibs of having AATD (25%) AND severe liver disease in childhood (40%) is 10%.</div></li><li class="half_rhythm"><div>If an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual did not have severe liver disease in childhood or if the liver disease resolved, the risk to sibs of having AATD (25%) AND liver disease (13%) is 3.3%.</div></li></ul><p><b>Family planning.</b> The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="alpha1-a.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SERPINA1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for AATD are possible.</p><p>Note: Prenatal testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression of the disorder. Fetal testing is not recommended in the American Thoracic Society/European Respiratory Society <a href="#alpha1-a.References">guidelines</a> because of the <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> of disease and the possibility that individuals with severe deficiency of AAT can have a normal life span and escape disease, especially if they never smoke [<a class="bk_pop" href="#alpha1-a.REF1">American Thoracic Society &#x00026; European Respiratory Society 2003</a>].</p><p>Because some children with AATD develop severe liver disease in the newborn period, and some of these children have a poor outcome, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> may be of interest to some at-risk couples who have previously had a child with severe liver disease (see <a href="#alpha1-a.Related_Genetic_Counseling_Issu">Related Genetic Counseling Issues</a>, <b>Risk to sibs of developing severe liver disease in infancy</b>).</p></div></div><div id="alpha1-a.Resources"><h2 id="_alpha1-a_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Alpha-1 Advocacy Alliance</b></div><div>103 Rapidan Church Lane</div><div>PO Box 202</div><div>Wolftown VA 22748</div><div><b>Phone:</b> 866-367-2122 (toll-free); 540-948-6777</div><div><b>Fax:</b> 540-948-6763</div><div><b>Email:</b> alpha1advocacyalliance@yahoo.com</div><div><a href="https://www.alpha1.org/Newly-Diagnosed/Living-with-Alpha-1/Support-Groups" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha-1 Advocacy Alliance</a></div></li><li class="half_rhythm"><div><b>Alpha-1 Association</b></div><div>2937 Southwest 27 Avenue</div><div>Suite 106</div><div>Miami FL 33133</div><div><b>Phone:</b> 800-521-3025 (toll-free); 305-648-0088</div><div><b>Fax:</b> 305-648-0089</div><div><b>Email:</b> info@alpha1.org</div><div><a href="http://www.alpha1.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alpha1.org</a></div></li><li class="half_rhythm"><div><b>Alpha-1 Association Genetic Counseling Program</b></div><div><i>The center offers free and confidential <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> to families with Alpha-1 Antitrypsin Deficiency.</i></div><div>Alpha-1 Association</div><div>2937 SW 27 Avenue</div><div>Suite 106</div><div>Miami FL 33133</div><div><b>Phone:</b> 800-785-3177 (toll-free)</div><div><a href="http://www.alpha1.org/support/genetic-counseling-program" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alpha1.org/support/genetic-counseling-program</a></div></li><li class="half_rhythm"><div><b>Alpha-1 Canada</b></div><div>1638 Northway Avenue</div><div>Windsor Ontario N9B 3L9</div><div>Canada</div><div><b>Phone:</b> 888-669-4583 (toll-free); 519-258-1444</div><div><b>Fax:</b> 519-258-1614</div><div><b>Email:</b> info@alpha1canada.ca</div><div><a href="http://www.alpha1canada.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alpha1canada.ca</a></div></li><li class="half_rhythm"><div><b>Alpha-1 Foundation</b></div><div>3300 Ponce de Leon Boulevard</div><div>Coral Gables FL 33134</div><div><b>Phone:</b> 877-228-7321; 305-567-9888</div><div><b>Fax:</b> 305-567-1317</div><div><b>Email:</b> info@alpha-1foundation.org</div><div><a href="http://www.alpha-1foundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alpha-1foundation.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Alpha-1%20Antitrypsin%20Deficiency&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha-1 Antitrypsin Deficiency</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=alpha1antitrypsindeficiency;jsessionid=D4E2E078605EC9CE8599D96BB81EBC0E" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Apha-1 antitrypsin deficiency</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22199/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha -1-antitrypsin deficiency</a></div></li><li class="half_rhythm"><div><b>American Liver Foundation</b></div><div>75 Maiden Lane</div><div>Suite 603</div><div>New York NY 10038</div><div><b>Phone:</b> 800-465-4837 (Toll-free HelpLine); 212-668-1000</div><div><b>Fax:</b> 212-483-8179</div><div><b>Email:</b> info@liverfoundation.org</div><div><a href="http://www.liverfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.liverfoundation.org</a></div></li><li class="half_rhythm"><div><b>Canadian Liver Foundation (CLF)</b></div><div>2235 Sheppard Avenue East</div><div>Suite 1500</div><div>Toronto Ontario M2J 5B5</div><div>Canada</div><div><b>Phone:</b> 800-563-5483 (toll-free); 416-491-3353</div><div><b>Fax:</b> 416-491-4952</div><div><b>Email:</b> clf@liver.ca</div><div><a href="http://www.liver.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.liver.ca</a></div></li><li class="half_rhythm"><div><b>Childhood Liver Disease Research and Education Network (ChiLDREN)</b></div><div><b>Phone:</b> 720-777-2598</div><div><b>Email:</b> joan.hines@childrenscolorado.org</div><div><a href="https://childrennetwork.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.childrennetwork.org</a></div></li><li class="half_rhythm"><div><b>Children's Liver Disease Foundation (CLDF)</b></div><div>36 Great Charles Street</div><div> Birmingham B3 3JY</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 121 212 3839</div><div><b>Fax:</b> +44 (0) 121 212 4300</div><div><b>Email:</b> info@childliverdisease.org</div><div><a href="http://www.childliverdisease.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.childliverdisease.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div>RareCareSM</div><div><b>Phone:</b> 800-999-6673</div><div><a href="https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs-2/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Assistance Programs</a></div></li><li class="half_rhythm"><div><b>Alpha-1 Canadian Registry</b></div><div>Toronto Western Hospital</div><div>399 Bathurst Street</div><div>7th Floor, East Wing, Room 445</div><div>Toronto Ontario M5T 2S8</div><div>Canada</div><div><b>Phone:</b> 800-352-8186 (toll-free); 416-603-5020</div><div><b>Fax:</b> 416-603-5020</div><div><b>Email:</b> alpha1canadianregistry@gmail.com</div><div><a href="http://www.alpha1canadianregistry.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alpha1canadianregistry.com</a></div></li><li class="half_rhythm"><div><b>Alpha-1 Foundation - National and International Registries</b></div><div><b>Phone:</b> 800-245-6809</div><div><a href="https://www.alpha1.org/Investigators/Resources/National-International-Registries" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alpha1.org/Investigators/Resources/National-International-Registries</a></div></li></ul></div><div id="alpha1-a.Molecular_Genetics"><h2 id="_alpha1-a_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="alpha1-a.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Alpha-1 Antitrypsin Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1519/table/alpha1-a.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpha1-a.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_alpha1-a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_alpha1-a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_alpha1-a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_alpha1-a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_alpha1-a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_alpha1-a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_alpha1-a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5265" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SERPINA1</i></a></td><td headers="hd_b_alpha1-a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5265" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q32<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_alpha1-a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01009" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha-1-antitrypsin</a></td><td headers="hd_b_alpha1-a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=SERPINA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (SERPINA1)</a></td><td headers="hd_b_alpha1-a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SERPINA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SERPINA1</a></td><td headers="hd_b_alpha1-a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SERPINA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SERPINA1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="alpha1-a.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="alpha1-a.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Alpha-1 Antitrypsin Deficiency (<a href="/omim/107400,613490" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1519/table/alpha1-a.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpha1-a.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/107400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">107400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 1; SERPINA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613490" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613490</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</td></tr></tbody></table></div></div><div id="alpha1-a.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>The basis for pulmonary disease in alpha-1 antitrypsin deficiency (AATD) is a reduced inhibition of neutrophil elastase that is always in the lung (and increased in smokers), resulting in excessive destruction of the elastin in the alveolar walls. Thus, lung disease is considered to result from a "toxic loss of function."</p><p>In contrast, liver disease in AATD is deemed the result of a "toxic gain of function" in which AAT encoded by pathogenic <i>SERPINA1</i> alleles polymerizes within the hepatocyte (through a mechanism called "loop-sheet polymerization") [<a class="bk_pop" href="#alpha1-a.REF.carrell.2002.45">Carrell &#x00026; Lomas 2002</a>], precluding secretion and allowing intra-hepatocyte accumulation of AAT protein. Through incompletely understood mechanisms, this accumulation of AAT protein is associated with liver disease. Ineffective clearance of abnormal AAT protein from the hepatocyte by protein chaperones has been suggested as a factor contributing to the liver disease [<a class="bk_pop" href="#alpha1-a.REF.kopito.2000.e207">Kopito &#x00026; Ron 2000</a>, <a class="bk_pop" href="#alpha1-a.REF.perlmutter.2002.1579">Perlmutter 2002</a>]. Of note, the role of enhancing autophagy in the liver (e.g., by administering carbamazepine or rapamycin) is being actively investigated [<a class="bk_pop" href="#alpha1-a.REF.hidvegi.2010.229">Hidvegi et al 2010</a>, <a class="bk_pop" href="#alpha1-a.REF.kaushal.2010.700">Kaushal et al 2010</a>, <a class="bk_pop" href="#alpha1-a.REF.perlmutter.2011.333">Perlmutter 2011</a>].</p><p>While uncertain, the pathogenic mechanism of polyangiitis with granulomatosis may relate to unopposed expression of c-ANCA, a substrate for AAT [<a class="bk_pop" href="#alpha1-a.REF.mahr.2010.3760">Mahr et al 2010</a>].</p><p><b>Gene structure.</b>
<i>SERPINA1</i> comprises five exons and has a total length of 12.2 kb. There are two promoters, with one controlling expression in macrophages. Multiple transcript variants are reported; however, they all encode the same AAT protein (for an explanation of nomenclature, see <a href="#alpha1-a.Diagnosis">Diagnosis</a>, <b>Electrophoretic ATT protein variants (<a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>)</b> and <b>Detection of a functionally deficient AAT protein variant by protease inhibitor typing</b>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1519/#alpha1-a.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Many benign variants of <i>SERPINA1</i>, which have no disease association, have been described. Benign variants of the normal PI*M <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (e.g., PI*M1, PI*M2) have also been described.</p><p>The normal PI*M <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is prevalent in some populations, particularly in Italy, and usually occurs in the <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state with the PI*S allele (i.e., PI*MS), as seen in approximately 8% of persons of northern European heritage.</p><p><b>Pathogenic variants.</b> Ninety-five percent of AATD-related disease results from homozygosity for the common <i>SERPINA1</i> PI*Z deficiency alleles (i.e., PI*ZZ).</p><p>At least 20 rare deficiency alleles and at least 14 <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles, found in many populations, comprise the remaining 5% of deficiency alleles.</p><ul><li class="half_rhythm"><div>The protein product of PI*M<sub>malton</sub>, like the protein product of the PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, aggregates in the liver (<a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.serpina1_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figalpha1aTserpina1pathogenicvariants" rid-ob="figobalpha1aTserpina1pathogenicvariants">Table 4</a>).</div></li><li class="half_rhythm"><div>Other deficiency alleles include PI*<sub>Siiyama</sub> (<a class="figpopup" href="/books/NBK1519/table/alpha1-a.T.serpina1_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figalpha1aTserpina1pathogenicvariants" rid-ob="figobalpha1aTserpina1pathogenicvariants">Table 4</a>).</div></li><li class="half_rhythm"><div><i>SERPINA1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles do not produce detectable serum AAT protein.</div></li></ul><div id="alpha1-a.T.serpina1_pathogenic_variants" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>SERPINA1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1519/table/alpha1-a.T.serpina1_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpha1-a.T.serpina1_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SERPINA1</i> Common Allele Name</th><th id="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Common Designation&#x000a0;<sup>1</sup>)</th><th id="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequence</th></tr></thead><tbody><tr><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PI*Z</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1096G&#x0003e;A</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu366Lys<br />(Glu342Lys)</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000295.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000295<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000286.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000286<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PI*S</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.863A&#x0003e;T</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu288Val<br />(Glu264Val)</td></tr><tr><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PI*M<sub>malton</sub></td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.226_228del</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe76del<br />(Phe52del)</td></tr><tr><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PI*<sub>Siiyama</sub></td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.230C&#x0003e;T</td><td headers="hd_h_alpha1-a.T.serpina1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser77Phe<br />(Ser53Phe)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors.&#x000a0;<i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: GeneReviews&#x000a0;follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="alpha1-a.TF.4.1"><p class="no_margin">Commonly used protein designations that do not conform to current naming conventions, which include the signal sequence of the reference protein <a href="/protein/NP_000286.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000286<wbr style="display:inline-block"></wbr>​.3</a> thereby increasing the amino acid codon number by 24 amino acids for each variant.</p></div></dd></dl></div></div></div><p>See <a href="/books/NBK1519/bin/alpha1-a-Table5.pdf">Table 5</a> (pdf) for additional information on selected <i>SERPINA1</i> variants.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Alpha-1 antitrypsin (AAT), a 52-kd glycoprotein, is a member of the serum protease inhibitor (serpin) family. The molecule is composed of 418 amino acids; the first 24 are the signal peptide, while residues 25-418 encode the mature protein. AAT provides &#x0003e;90% of the protection against neutrophil elastase in the lower airways.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The Z protein variant (encoded by the PI*Z <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) polymerizes within the hepatocyte before being secreted. Polymers of Z protein variants are also produced by alveolar macrophages and have been shown to be chemotactic for neutrophils. Thus, in addition to being ascribed to a "toxic loss of function" mechanism, lung destruction may be fueled by an inflammatory reaction related to the polymers of Z protein variants in the lung [<a class="bk_pop" href="#alpha1-a.REF.mcelvaney.1997.394">McElvaney et al 1997</a>].</p><p>Other protein variants, such as the S variant protein encoded by the PI*S <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, are more easily degraded.</p><p>Others are not translated because of unstable <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (RNA decay), are truncated and rendered nonfunctional, or may cause conformational change, leading to intracellular polymerization.</p><p>Null variant alleles do not produce serum AAT [<a class="bk_pop" href="#alpha1-a.REF.brantly.1988.13">Brantly et al 1988</a>, <a class="bk_pop" href="#alpha1-a.REF.cox.1989.844">Cox &#x00026; Billingsley 1989</a>, <a class="bk_pop" href="#alpha1-a.REF.faber.1994.1113">Faber et al 1994</a>].</p></div></div><div id="alpha1-a.References"><h2 id="_alpha1-a_References_">References</h2><div id="alpha1-a.Published_Guidelines__Consensus"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF1">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Available <a href="http://www.atsjournals.org/doi/full/10.1164/rccm.168.7.818" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2003. Accessed 3-1-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.marciniuk.2012">Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, Lauzon JL, Maltais F, O'Donnell DE, Goodridge D, Strange C, Cave AJ, Curren K, Muthuri S; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. 2012. [<a href="/pmc/articles/PMC3373286/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3373286</span></a>] [<a href="/pubmed/22536580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22536580</span></a>]</div></li></ul></div><div id="alpha1-a.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.abusriwil.2006.125">Abusriwil H, Stockley RA. Alpha-1 antitrypsin replacement therapy: current status. <span><span class="ref-journal">Curr Opin Pulm Med. </span>2006;<span class="ref-vol">12</span>:125–31.</span> [<a href="/pubmed/16456382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16456382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.aadrsg.1998.49">AADRSG.  Survival and FEV1 decline in individuals with severe deficiency of alpha-1 antitrypsin (Alpha-1 Antitrypsin Deficiency Registry Study Group). <span><span class="ref-journal">Am J Respir Crit Care Med. </span>1998;<span class="ref-vol">158</span>:49–59.</span> [<a href="/pubmed/9655706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9655706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.american_thoracic_society_european_respiratory_society.2003.818">American Thoracic Society, European Respiratory Society.  American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2003;<span class="ref-vol">168</span>:818–900.</span> [<a href="/pubmed/14522813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14522813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.bernsp_ng.2009.861">Bernsp&#x000e5;ng E, Wollmer P, Sveger T, Piitulainen E. Lung function in 30-year-old alpha-1 antitrypsin-deficient individuals. <span><span class="ref-journal">Respir Med. </span>2009;<span class="ref-vol">103</span>:861–5.</span> [<a href="/pubmed/19181511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19181511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.bornhorst.2013.1000">Bornhorst JA, Greene DN, Ashwood ER, Grenache DG. &#x003b1;1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. <span><span class="ref-journal">Chest. </span>2013;<span class="ref-vol">143</span>:1000–8.</span> [<a href="/pubmed/23632999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23632999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.brantly.1988.13">Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Am J Med. </span>1988;<span class="ref-vol">84</span>:13–31.</span> [<a href="/pubmed/3289385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3289385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.brantly.1991.703">Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Use of a highly purified alpha-1 antitrypsin standard to establish ranges for the common normal and deficient alpha-1 antitrypsin phenotypes. <span><span class="ref-journal">Chest. </span>1991;<span class="ref-vol">100</span>:703–8.</span> [<a href="/pubmed/1889260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1889260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.bruix.2005.1208">Bruix J, Sherman M., Practice Guidelines Committee, American Association for the Study of Liver Diseases.  Management of hepatocellular carcinoma. <span><span class="ref-journal">Hepatology. </span>2005;<span class="ref-vol">42</span>:1208–36.</span> [<a href="/pubmed/16250051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16250051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.burrows.2000.1796">Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha-1 antitrypsin (alpha-1 AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha-1 AT deficiency. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2000;<span class="ref-vol">97</span>:1796–801.</span> [<a href="/pmc/articles/PMC26515/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC26515</span></a>] [<a href="/pubmed/10677536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10677536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.campbell.2000">Campbell EJ. Alpha-1 antitrypsin deficiency: incidence and detection program. Respir Med 2000; 94 Suppl C:18-21. [<a href="/pubmed/10954251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10954251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.carrell.2002.45">Carrell RW, Lomas DA. Alpha-1 antitrypsin deficiency--a model for conformational diseases. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:45–53.</span> [<a href="/pubmed/11778003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11778003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.carey.2013.1370">Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes in liver transplant recipients for alpha-1 antitrypsin deficiency related cirrhosis. <span><span class="ref-journal">Liver Transpl. </span>2013;<span class="ref-vol">19</span>:1370–6.</span> [<a href="/pubmed/24019185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24019185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.casolaro.1987.2015">Casolaro MA, Fells G, Wewers M, Pierce JE, Ogushi F, Hubbard R, Sellers S, Forstrom J, Lyons D, Kawasaki G, Crystal RG. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1 antitrypsin. <span><span class="ref-journal">J Appl Physiol. </span>1987;<span class="ref-vol">63</span>:2015–23.</span> [<a href="/pubmed/3500941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3500941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cassina.1998.1028">Cassina PC, Teschler H, Konietzko N, Theegarten D, Stamatis G. Two-year results after lung volume reduction surgery in alpha-1 antitrypsin deficiency versus smoker's emphysema. <span><span class="ref-journal">Eur Respir J. </span>1998;<span class="ref-vol">12</span>:1028–32.</span> [<a href="/pubmed/9863992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9863992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.chapman.2013.a6069">Chapman KR, Burdon JGW, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Huang L, Edelman JM, McElvaney NG. IV Alpha-1 antitrypsin (A1AT) preserves lung density In homozygous Alpha-1 antitrypsin deficiency (A1ATD): A randomized, placebo-controlled trial. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2013;<span class="ref-vol">187</span>:A6069.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.clark.2012.1278">Clark VC, Dhanasekaran R, Brantly M, Rouhani F, Schreck P, Nelson DR. Liver test results do not identify liver disease in adults with &#x003b1;(1)-antitrypsin deficiency. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2012;<span class="ref-vol">10</span>:1278–83.</span> [<a href="/pmc/articles/PMC3482934/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3482934</span></a>] [<a href="/pubmed/22835581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22835581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cox.1979.467">Cox DW, Talamo RC. Genetic aspects of pediatric lung disease. <span><span class="ref-journal">Pediatr Clin North Am. </span>1979;<span class="ref-vol">26</span>:467–80.</span> [<a href="/pubmed/315047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 315047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cox.1980.429">Cox DW, Johnson AM, Fagerhol M. Report of nomenclature meeting for alpha-1 antitrypsin. <span><span class="ref-journal">Hum Genet. </span>1980;<span class="ref-vol">53</span>:429–33.</span> [<a href="/pubmed/6102963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6102963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cox.1983.221">Cox DW, Smyth S. Risk for liver disease in adults with alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Am J Med. </span>1983;<span class="ref-vol">74</span>:221–7.</span> [<a href="/pubmed/6600583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6600583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cox.1989.844">Cox DW, Billingsley GD. Rare deficiency types of alpha-1 antitrypsin: electrophoretic variation and DNA haplotypes. <span><span class="ref-journal">Am J Hum Genet. </span>1989;<span class="ref-vol">44</span>:844–54.</span> [<a href="/pmc/articles/PMC1715659/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715659</span></a>] [<a href="/pubmed/2786333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2786333</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cox.2004.468">Cox DW. Prenatal diagnosis for alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Prenat Diagn. </span>2004;<span class="ref-vol">24</span>:468–70.</span> [<a href="/pubmed/15229848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15229848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.cutz.1979.1">Cutz E, Cox DW. Alpha-1 antitrypsin deficiency: the spectrum of pathology and pathophysiology. <span><span class="ref-journal">Perspect Pediatr Pathol. </span>1979;<span class="ref-vol">5</span>:1–39.</span> [<a href="/pubmed/231756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 231756</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.dawwas.2013.502">Dawwas MF, Davies SE, Griffiths WJH, Lomas DA, Alexander GJ. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2013;<span class="ref-vol">187</span>:502–8.</span> [<a href="/pubmed/23262512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23262512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.demeo.2008.114">Demeo DL, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK. IL10 polymorphisms are associated with airflow obstruction in severe alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Am J Respir Cell Mol Biol. </span>2008;<span class="ref-vol">38</span>:114–20.</span> [<a href="/pmc/articles/PMC2176135/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2176135</span></a>] [<a href="/pubmed/17690329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17690329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.de_serres.2012.277">de Serres FJ, Blanco I. Prevalence of &#x003b1;1-antitrypsin deficiency alleles PI*Sand PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. <span><span class="ref-journal">Ther Adv Respir Dis. </span>2012;<span class="ref-vol">6</span>:277–95.</span> [<a href="/pubmed/22933512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22933512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.dirksen.1999.1468">Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J. A randomized clinical trial of alpha-1 antitrypsin augmentation therapy. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>1999;<span class="ref-vol">160</span>:1468–72.</span> [<a href="/pubmed/10556107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10556107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.dirksen.2009.1345">Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA. Exploring the role of CT densitometry: a randomised study of augmentation therapyin alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Eur Respir J. </span>2009;<span class="ref-vol">33</span>:1345–53.</span> [<a href="/pubmed/19196813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19196813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.donato.2012.398">Donato LJ, Jenkins SM, Smith C, Katzmann JA, Snyder MR. Reference and interpretive ranges for &#x003b1;(1)-antitrypsin quantitation by phenotype in adult and pediatric populations. <span><span class="ref-journal">Am J Clin Pathol. </span>2012 Sep;<span class="ref-vol">138</span>:398–405.</span> [<a href="/pubmed/22912357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22912357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.eden.2003.765">Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, Fallat RJ, Stoller JK, Crystal RG, Turino GM. Asthma features in severe alpha-1 antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. <span><span class="ref-journal">Chest. </span>2003;<span class="ref-vol">123</span>:765–71.</span> [<a href="/pubmed/12628876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12628876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.eriksson.1987.461">Eriksson S. Alpha-1 antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases. <span><span class="ref-journal">Acta Med Scand. </span>1987;<span class="ref-vol">221</span>:461–7.</span> [<a href="/pubmed/3496734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3496734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.faber.1994.1113">Faber JP, Poller W, Weidinger S, Kirchgesser M, Schwaab R, Bidlingmaier F, Olek K. Identification and DNA sequence analysis of 15 new alpha-1 antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele. <span><span class="ref-journal">Am J Hum Genet. </span>1994;<span class="ref-vol">55</span>:1113–21.</span> [<a href="/pmc/articles/PMC1918455/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1918455</span></a>] [<a href="/pubmed/7977369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7977369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.ferrarotti.2012.669">Ferrarotti I, Thun GA, Zorzetto M, Ottaviani S, Imboden M, Schindler C, von Eckardstein A, Rohrer L, Rochat T, Russi EW, Probst-Hensch NM, Luisetti M. Serum levels and genotype distribution of &#x003b1;1-antitrypsin in the general population. <span><span class="ref-journal">Thorax. </span>2012;<span class="ref-vol">67</span>:669–74.</span> [<a href="/pubmed/22426792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22426792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.fischler.2001a.88">Fischler B, Papadogiannakis N, Nemeth A. Aetiological factors in neonatal cholestasis. <span><span class="ref-journal">Acta Paediatr. </span>2001a;<span class="ref-vol">90</span>:88–92.</span> [<a href="/pubmed/11227341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11227341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.fischler.2001b.171">Fischler B, Papadogiannakis N, Nemeth A. Clinical aspects on neonatal cholestasis based on observations at a Swedish tertiary referral centre. <span><span class="ref-journal">Acta Paediatr. </span>2001b;<span class="ref-vol">90</span>:171–8.</span> [<a href="/pubmed/11236047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11236047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.fishman.2003.2059">Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE, et al.  A randomized trial comparing lung-volume&#x02013;reduction surgery with medical therapy for severe emphysema. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">348</span>:2059–73.</span> [<a href="/pubmed/12759479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12759479</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.flotte.2011.1239">Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG, Mueller C, Messina LM, Wilson JM, Brantly M, Knop DR, Ye GJ, Chulay JD. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing &#x003b1;1-antitrypsin: interim results. <span><span class="ref-journal">Hum Gene Ther. </span>2011;<span class="ref-vol">22</span>:1239–47.</span> [<a href="/pmc/articles/PMC3205788/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3205788</span></a>] [<a href="/pubmed/21609134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21609134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.francavilla.2000.986">Francavilla R, Castellaneta SP, Hadzic N, Chambers SM, Portmann B, Tung J, Cheeseman P, Rela M, Heaton ND, Mieli-Vergani G. Prognosis of alpha-1 antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. <span><span class="ref-journal">J Hepatol. </span>2000;<span class="ref-vol">32</span>:986–92.</span> [<a href="/pubmed/10898319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10898319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.gelb.1999.928">Gelb AF, McKenna RJ, Brenner M, Fischel R, Zamel N. Lung function after bilateral lower lobe lung volume reduction surgery for alpha-1 antitrypsin emphysema. <span><span class="ref-journal">Eur Respir J. </span>1999;<span class="ref-vol">14</span>:928–33.</span> [<a href="/pubmed/10573244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10573244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.graziadei.1998.1058">Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Hepatology. </span>1998;<span class="ref-vol">28</span>:1058–63.</span> [<a href="/pubmed/9755243" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9755243</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.greene.2013.184">Greene DN, Elliott-Jelf MC, Straseski JA, Grenache DG. Facilitating the laboratory diagnosis of &#x003b1;1-antitrypsin deficiency. <span><span class="ref-journal">Am J Clin Pathol. </span>2013;<span class="ref-vol">139</span>:184–91.</span> [<a href="/pubmed/23355203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23355203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.hersh.2004.843">Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha-1 antitrypsin PI MZ heterozygotes: a meta-analysis. <span><span class="ref-journal">Thorax. </span>2004;<span class="ref-vol">59</span>:843–9.</span> [<a href="/pmc/articles/PMC1746834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1746834</span></a>] [<a href="/pubmed/15454649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15454649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.hidvegi.2010.229">Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N, Mukherjee A, Goldbach C, Watkins S, Michalopoulos G, Perlmutter DH. An autophagy enhancing drug promotes degradation of mutant alpha-1 antitrypsin Z and reduces hepatic fibrosis. <span><span class="ref-journal">Science. </span>2010;<span class="ref-vol">329</span>:229–32.</span> [<a href="/pubmed/20522742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20522742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.hubbard.1990.565">Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha-1 antitrypsin deficiency by the aerosol route. <span><span class="ref-journal">Lung. </span>1990;<span class="ref-vol">168</span> Suppl:565–78.</span> [<a href="/pubmed/2117165" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2117165</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.kaushal.2010.700">Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM, Teckman JH. Rapamycin reduces intrahepatic alpha-1 antitrypsin mutant Z protein polymers and liver injury in a mousemodel. <span><span class="ref-journal">Exp Biol Med (Maywood). </span>2010;<span class="ref-vol">235</span>:700–9.</span> [<a href="/pmc/articles/PMC3763806/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3763806</span></a>] [<a href="/pubmed/20511674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20511674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.kershaw.2008.66">Kershaw CD, Guidot DM. Alcoholic lung disease. <span><span class="ref-journal">Alcohol Research &#x00026; Health. </span>2008;<span class="ref-vol">31</span>:66–75.</span> [<a href="/pmc/articles/PMC3860447/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3860447</span></a>] [<a href="/pubmed/23584753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23584753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.kopito.2000.e207">Kopito RR, Ron D. Conformational disease. <span><span class="ref-journal">Nat Cell Biol. </span>2000;<span class="ref-vol">2</span>:E207–9.</span> [<a href="/pubmed/11056553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11056553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.lima.2001.287">Lima LC, Matte U, Leistner S, Bopp AR, Scholl VC, Giugliani R, da Silveira TR. Molecular analysis of the Pi*Z allele in patients with liver disease. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">104</span>:287–90.</span> [<a href="/pubmed/11754061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11754061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.luisetti.2004.164">Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. <span><span class="ref-journal">Thorax. </span>2004;<span class="ref-vol">59</span>:164–9.</span> [<a href="/pmc/articles/PMC1746939/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1746939</span></a>] [<a href="/pubmed/14760160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14760160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.mahadeva.2002.6771">Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:6771–4.</span> [<a href="/pubmed/11773044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11773044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.mahr.2010.3760">Mahr AD, Edberg JC, Stone JH, Hoffman GS, St Clair EW, Specks U, Dellaripa PF, Seo P, Spiera RF, Rouhani FN, Brantly ML, Merkel PA. Alpha-1 antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <span><span class="ref-journal">Arthritis Rheum. </span>2010;<span class="ref-vol">62</span>:3760–7.</span> [<a href="/pmc/articles/PMC3123032/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3123032</span></a>] [<a href="/pubmed/20827781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20827781</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.marciniuk.2012.109">Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, Lauzon JL, Maltais F, O'Donnell DE, Goodridge D, Strange C, Cave AJ, Curren K, Muthuri S, et al.  Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. <span><span class="ref-journal">Can Respir J. </span>2012;<span class="ref-vol">19</span>:109–16.</span> [<a href="/pmc/articles/PMC3373286/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3373286</span></a>] [<a href="/pubmed/22536580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22536580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.mcelvaney.1997.394">McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, Crystal RD. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha-1 antitrypsin deficiency. Alpha-1Antitrypsin Deficiency Registry Study Group. <span><span class="ref-journal">Chest. </span>1997;<span class="ref-vol">111</span>:394–403.</span> [<a href="/pubmed/9041988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9041988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.migliazza.2000.5">Migliazza L, Lopez Santamaria M, Murcia J, Gamez M, Clavijo J, Camarena C, Hierro L, Frauca E, de la Vega A, Diaz M, Jara P, Tovar JA. Long-term survival expectancy after liver transplantation in children. <span><span class="ref-journal">J Pediatr Surg. </span>2000;<span class="ref-vol">35</span>:5–7.</span> [<a href="/pubmed/10646764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10646764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.miravitlles.2000">Miravitlles M. Alpha-1 antitrypsin deficiency: epidemiology and prevalence. Respir Med 2000; 94 Suppl C:S12-5. [<a href="/pubmed/10954249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10954249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.miravitlles.2003.404">Miravitlles M, Vila S, Jardi R, de la Roza C, Rodriguez-Frias F, Vidal R. Emphysema due to alpha-1 antitrypsin deficiency: familial study of the YBARCELONA variant. <span><span class="ref-journal">Chest. </span>2003;<span class="ref-vol">124</span>:404–6.</span> [<a href="/pubmed/12853554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12853554</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.nelson.2012.575">Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with &#x003b1;1-antitrypsin (A1AT) deficiency. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2012;<span class="ref-vol">10</span>:575–80.</span> [<a href="/pmc/articles/PMC3360829/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3360829</span></a>] [<a href="/pubmed/22200689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22200689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.parfrey.2004.133">Parfrey H, Dafforn TR, Belorgey D, Lomas DA, Mahadeva R. Inhibiting polymerization: new therapeutic strategies for Z alpha-1 antitrypsin-related emphysema. <span><span class="ref-journal">Am J Respir Cell Mol Biol. </span>2004;<span class="ref-vol">31</span>:133–9.</span> [<a href="/pubmed/15016619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15016619</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.parr.2004.1172">Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in alpha-1 antitrypsin deficiency influences lung function impairment. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2004;<span class="ref-vol">170</span>:1172–8.</span> [<a href="/pubmed/15306534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15306534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.parr.2007.1215">Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha-1antitrypsin deficiency. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2007;<span class="ref-vol">176</span>:1215–21.</span> [<a href="/pubmed/17872489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17872489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.perlmutter.2002.1579">Perlmutter DH. Liver injury in alpha-1 antitrypsin deficiency: an aggregated protein induces mitochondrial injury. <span><span class="ref-journal">J Clin Invest. </span>2002;<span class="ref-vol">110</span>:1579–83.</span> [<a href="/pmc/articles/PMC151639/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC151639</span></a>] [<a href="/pubmed/12464659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12464659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.perlmutter.2006.233">Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Pediatr Res. </span>2006;<span class="ref-vol">60</span>:233–8.</span> [<a href="/pubmed/16864711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16864711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.perlmutter.2011.333">Perlmutter DH. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. <span><span class="ref-journal">Annu Rev Med. </span>2011;<span class="ref-vol">62</span>:333–45.</span> [<a href="/pubmed/20707674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20707674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.pittschieler.2002.239">Pittschieler K. Liver involvement in alpha-1 antitrypsin-deficient phenotypes PiSZ and PiMZ. <span><span class="ref-journal">Acta Paediatr. </span>2002;<span class="ref-vol">91</span>:239–40.</span> [<a href="/pubmed/11952016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11952016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.pittschieler.1991.235">Pittschieler K. Oxidative radicals and liver involvement of infants with alpha-1-antitrypsin deficiency. <span><span class="ref-journal">Padiatr Padol. </span>1991;<span class="ref-vol">26</span>:235–7.</span> [<a href="/pubmed/1663223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1663223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.sandhaus.2004.904">Sandhaus RA. Alpha-1 antitrypsin deficiency. 6: new and emerging treatments for alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Thorax. </span>2004;<span class="ref-vol">59</span>:904–9.</span> [<a href="/pmc/articles/PMC1746849/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1746849</span></a>] [<a href="/pubmed/15454659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15454659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.seersholm.1994.1985">Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Eur Respir J. </span>1994;<span class="ref-vol">7</span>:1985–7.</span> [<a href="/pubmed/7875269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7875269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.seersholm.1997.2260">Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N. Does alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1 antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) Alpha-1 AT study group. <span><span class="ref-journal">Eur Respir J. </span>1997;<span class="ref-vol">10</span>:2260–3.</span> [<a href="/pubmed/9387950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9387950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.smith.2014.94.e7">Smith BM, Austin JH, Newell JD Jr, D'Souza BM, Rozenshtein A, Hoffman EA, Ahmed F, Barr RG. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study. <span><span class="ref-journal">Am J Med. </span>2014;<span class="ref-vol">127</span>:94.e7–23.</span> [<a href="/pmc/articles/PMC3882898/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3882898</span></a>] [<a href="/pubmed/24384106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24384106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.sokol.1986.1263">Sokol RJ, Heubi JE, McGraw C, Balistreri WF. Correction of vitamin E deficiency in children with chronic cholestasis. II. Effect on gastrointestinal and hepatic function. <span><span class="ref-journal">Hepatology. </span>1986;<span class="ref-vol">6</span>:1263–9.</span> [<a href="/pubmed/3793002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3793002</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.s_rheim.2010.1125">S&#x000f8;rheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agust&#x000ed; A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, Par&#x000e9; PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK. &#x003b1;<sub>1</sub>-antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. <span><span class="ref-journal">Chest. </span>2010;<span class="ref-vol">138</span>:1125–32.</span> [<a href="/pmc/articles/PMC2972629/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2972629</span></a>] [<a href="/pubmed/20595457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20595457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.stolk.2001.648">Stolk J, Dirksen A, van der Lugt AA, Hutsebaut J, Mathieu J, de Ree J, Reiber JH, Stoel BC. Repeatability of lung density measurements with low-dose computed tomography in subjects with alpha-1 antitrypsin deficiency-associated emphysema. <span><span class="ref-journal">Invest Radiol. </span>2001;<span class="ref-vol">36</span>:648–51.</span> [<a href="/pubmed/11606842" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11606842</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.stoller.2005.2225">Stoller JK, Aboussouan LS. Alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Lancet. </span>2005;<span class="ref-vol">365</span>:2225–36.</span> [<a href="/pubmed/15978931" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15978931</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.stoller.2007.241">Stoller JK, Gildea T, Meli Y, Karafa M, Ries A. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency: Experience in the National Emphysema Treatment Trial. <span><span class="ref-journal">Ann Thorac Surg. </span>2007;<span class="ref-vol">83</span>:241–51.</span> [<a href="/pubmed/17184672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17184672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.stoller.2008.113">Stoller JK, Piliang M. Panniculitis in alpha-1 antitrypsin deficiency: a review. <span><span class="ref-journal">Clin Pulm Med. </span>2008;<span class="ref-vol">15</span>:113–7.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.sveger.1985.3036">Sveger T. Breast feeding, alpha-1 antitrypsin deficiency, and liver disease? <span><span class="ref-journal">JAMA. </span>1985;<span class="ref-vol">254</span>:3036–7.</span> [<a href="/pubmed/3877179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3877179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.sveger.1976.1316">Sveger T. Liver disease in alpha-1 antitrypsin deficiency detected by screening of 200,000 infants. <span><span class="ref-journal">N Engl J Med. </span>1976;<span class="ref-vol">294</span>:1316–21.</span> [<a href="/pubmed/1083485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1083485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.sveger.1988.847">Sveger T. The natural history of liver disease in alpha-1 antitrypsin deficient children. <span><span class="ref-journal">Acta Paediatr Scand. </span>1988;<span class="ref-vol">77</span>:847–51.</span> [<a href="/pubmed/2905108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2905108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.tanash.2008.1091">Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1 antitrypsin deficiency (PiZZ). <span><span class="ref-journal">Thorax. </span>2008;<span class="ref-vol">63</span>:1091–5.</span> [<a href="/pubmed/18682522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18682522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.tanash.2011.1342">Tanash HA, Riise GC, Hansson L, Nilsson PM, Piitulainen E. Survival benefit of lung transplantation in individuals with severe &#x003b1;1-antitrypsin deficiency (PiZZ) and emphysema. <span><span class="ref-journal">J Heart Lung Transplant. </span>2011;<span class="ref-vol">30</span>:1342–7.</span> [<a href="/pubmed/21821433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21821433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.teckman.2004.34">Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1 antitrypsin in patients with alpha-1 antitrypsin deficiency: a preliminary study. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2004;<span class="ref-vol">39</span>:34–7.</span> [<a href="/pubmed/15187777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15187777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.tonelli.2009.443">Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1 antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. <span><span class="ref-journal">Int J Chron Obstruct Pulmon Dis. </span>2009;<span class="ref-vol">4</span>:443–52.</span> [<a href="/pmc/articles/PMC2802045/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2802045</span></a>] [<a href="/pubmed/20054436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20054436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.trulock.1998.269s">Trulock EP. Lung Transplantation for COPD. <span><span class="ref-journal">Chest. </span>1998;<span class="ref-vol">113</span>:269S–276S.</span> [<a href="/pubmed/9552017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9552017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.turino.1996.1718">Turino GM, Barker AF, Brantly ML, Cohen AB, Connelly RP, Crystal RG, Eden E, Schluchter MD, Stoller JK. Clinical features of individuals with PI*SZ phenotype of alpha-1 antitrypsin deficiency. Alpha-1 Antitrypsin Deficiency Registry Study Group. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>1996;<span class="ref-vol">154</span>:1718–25.</span> [<a href="/pubmed/8970361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8970361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.volpert.2000.258">Volpert D, Molleston JP, Perlmutter DH. Alpha-1 antitrypsin deficiency-associated liver disease progresses slowly in some children. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2000;<span class="ref-vol">31</span>:258–63.</span> [<a href="/pubmed/10997369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10997369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.wencker.1998.428">Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha-1 antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha-1 AT-study group. <span><span class="ref-journal">Eur Respir J. </span>1998;<span class="ref-vol">11</span>:428–33.</span> [<a href="/pubmed/9551749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9551749</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.wencker.2002.319">Wencker M, Marx A, Konietzko N, Schaefer B, Campbell EJ. Screening for alpha-1 Pi deficiency in patients with lung diseases. <span><span class="ref-journal">Eur Respir J. </span>2002;<span class="ref-vol">20</span>:319–24.</span> [<a href="/pubmed/12212962" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12212962</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.wright.1991.830">Wright G, Carver A, Cotton D, Reeves D, Scott A, Simons P, Wilmut I, Garner I, Colman A. High level expression of active human alpha-1 antitrypsin in the milk of transgenic sheep. <span><span class="ref-journal">Biotechnology (N Y). </span>1991;<span class="ref-vol">9</span>:830–4.</span> [<a href="/pubmed/1367357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1367357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.yesudian.2004.1222">Yesudian PD, Dobson CM, Wilson NJ. Alpha-1 antitrypsin deficiency panniculitis (phenotype PiZZ) precipitated postpartum and successfully treated with dapsone. <span><span class="ref-journal">Br J Dermatol. </span>2004;<span class="ref-vol">150</span>:1222–3.</span> [<a href="/pubmed/15214923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15214923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpha1-a.REF.ziomek.1998.139">Ziomek CA. Commercialization of proteins produced in the mammary gland. <span><span class="ref-journal">Theriogenology. </span>1998;<span class="ref-vol">49</span>:139–44.</span> [<a href="/pubmed/10732127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10732127</span></a>]</div></li></ul></div></div><div id="alpha1-a.Chapter_Notes"><h2 id="_alpha1-a_Chapter_Notes_">Chapter Notes</h2><div id="alpha1-a.Author_Notes"><h3>Author Notes</h3><p>Research Support, Non-US Government<br />Research Support, US Government, PHS<br /><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746834/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Review</a>. Thorax. 2004;59:843-9</p></div><div id="alpha1-a.Author_History"><h3>Author History</h3><p>Loutfi S Aboussouan, MD (2014-present)<br />Diane W Cox, PhD, FCCMG, FRSC; University of Alberta (2005-2014)<br />Felicitas L Lacbawan, MD (2014-present)<br />Kamilla Schlade-Bartusiak, PhD; University of Alberta (2005-2014)<br />James K Stoller, MD, MS (2014-present)</p></div><div id="alpha1-a.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>19 January 2017 (jks) Revision: clarification re serum levels of AAT in heterozygotes (<a href="#alpha1-a.Confirming_the_Diagnosis">Confirming the Diagnosis</a>)</div></li><li class="half_rhythm"><div>1 May 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 February 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available on a clinical basis</div></li><li class="half_rhythm"><div>27 October 2006 (me) Review posted to live Web site</div></li><li class="half_rhythm"><div>15 February 2005 (dc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1519</span><span class="label">PMID: <a href="/pubmed/20301692" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301692</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/alkap/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/a-mannosidosis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1519&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1519/?report=reader">PubReader</a></li><li><a href="/books/NBK1519/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1519" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1519" style="display:none" title="Cite this Page"><div class="bk_tt">Stoller JK, Lacbawan FL, Aboussouan LS. Alpha-1 Antitrypsin Deficiency. 2006 Oct 27 [Updated 2017 Jan 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1519/pdf/Bookshelf_NBK1519.pdf">PDF version of this page</a> (553K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#alpha1-a.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#alpha1-a.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#alpha1-a.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#alpha1-a.Genetically_Related_Allelic_Dis" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#alpha1-a.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#alpha1-a.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#alpha1-a.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#alpha1-a.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#alpha1-a.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#alpha1-a.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#alpha1-a.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5265[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SERPINA1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1494316" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1494316" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1494316" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1494316" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18565211" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.</a><span class="source">[Orphanet J Rare Dis. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fregonese L, Stolk J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2008 Jun 19; 3:16. Epub 2008 Jun 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23776367" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Alpha1-antitrypsin deficiency: a clinical-genetic overview.</a><span class="source">[Appl Clin Genet. 2011]</span><div class="brieflinkpop offscreen_noflow">Alpha1-antitrypsin deficiency: a clinical-genetic overview.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Abboud RT, Nelson TN, Jung B, Mattman A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Appl Clin Genet. 2011; 4:55-65. Epub 2011 Mar 31.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30254761" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations.</a><span class="source">[Pulm Med. 2018]</span><div class="brieflinkpop offscreen_noflow">Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Foil KE, Blanton MG, Sanders C, Kim J, Al Ashry HS, Kumbhare S, Strange C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pulm Med. 2018; 2018:2836389. Epub 2018 Sep 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31121167" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation.</a><span class="source">[Gastroenterology. 2019]</span><div class="brieflinkpop offscreen_noflow">Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hamesch K, Mandorfer M, Pereira VM, Moeller LS, Pons M, Dolman GE, Reichert MC, Schneider CV, Woditsch V, Voss J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterology. 2019 Sep; 157(3):705-719.e18. Epub 2019 May 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28929906" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.</a><span class="source">[Postgrad Med. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lascano JE, Campos MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Postgrad Med. 2017 Nov; 129(8):889-895. Epub 2017 Oct 5.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301692" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301692" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0415e875f66d18aa54097c">Alpha-1 Antitrypsin Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Alpha-1 Antitrypsin Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:07:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88B3EBE04077C100000000061C0244&amp;ncbi_session=CE88B3EBE0415E71_1564SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1519%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1519&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1519/&amp;ncbi_pagename=Alpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88B3EBE0415E71_1564SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>